<SEC-DOCUMENT>0001178913-17-003222.txt : 20171121
<SEC-HEADER>0001178913-17-003222.hdr.sgml : 20171121
<ACCEPTANCE-DATETIME>20171121162737
ACCESSION NUMBER:		0001178913-17-003222
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20171121
DATE AS OF CHANGE:		20171121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211065
		FILM NUMBER:		171217193

	BUSINESS ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>zk1720818.htm
<DESCRIPTION>424B5
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.3.3.0
    Copyright 1995 - 2017 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br>
<div id="DSPFPageHeader"></div>

<table id="z771fc6759229465f99e1f48f58c9215a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">Filed pursuant to Rule 424(b)(5)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Registration No. 333-211065</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">PROSPECTUS SUPPLEMENT<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (To the Prospectus Dated July 12, 2016)</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><img style="HEIGHT: 69px; WIDTH: 148px" src="image0.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2,272,640 Ordinary Shares</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We are offering <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,272,640 </font>ordinary shares, par value NIS 0.20 per share, directly to the investors in this offering at a price of $1.10 per share pursuant to this prospectus supplement and the accompanying prospectus. In a concurrent private placement, we are also selling to investors warrants to purchase an aggregate of up to 1,704,480 of our ordinary shares. The warrants will be exercisable on the date of issuance, at an exercise price of $1.25 per share, and will expire on the fifth anniversary of the initial issuance date. The warrants and the ordinary shares issuable upon the exercise of the warrants are not being registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the registration statement of which this prospectus supplement and the accompanying prospectus form a part and are not being offered pursuant to this prospectus supplement and the accompanying prospectus. The warrants and the ordinary shares issuable upon the exercise of the warrants are being offered pursuant to an exemption from the registration requirement of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule 506(c) of Regulation D.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our ordinary shares are traded on the Nasdaq Capital Market under the symbol &#8220;CHEK&#8221;. On November 20, 2017, the last reported sale price per shares of our ordinary share on the Nasdaq Capital Market was $1.09 per share.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Based on the reported sale price of $1.97 of our ordinary shares on the Nasdaq Capital Market on September 28, 2017, the aggregate market value of our public float, calculated according to General Instruction I.B.5 of Form F-3, is approximately $28,350,697.49. Under the registration statement to which this prospectus supplement forms a part, we may not sell our securities in a primary offering with a value exceeding one-third of our public float in any 12-month period (unless our public float rises to $75.0 million or more). During the 12 calendar months preceding the date of this prospectus supplement, we have sold $2,699,000 of securities pursuant to General Instruction I.B.5, and, accordingly, may sell up to $6,751,232 of ordinary shares hereunder.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus supplement, the accompanying prospectus and future filings with the Securities and Exchange Commission.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have retained H.C. Wainwright &amp; Co., LLC to act as our exclusive placement agent in connection with this offering to use its &#8220;reasonable best efforts&#8221; to solicit offers to purchase our ordinary shares. The placement agent is not purchasing or selling any of our ordinary shares offered pursuant to this prospectus supplement or the accompanying prospectus. See &#8220;Plan of Distribution&#8221; beginning on page S-12 of this prospectus supplement for more information regarding these arrangements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Investing in our securities involves a high degree of risk. We refer you to the section entitled &#8220;Risk Factors&#8221; on page S-5 of this prospectus supplement and on page 5 of the accompanying prospectus and under similar sections in the documents we incorporate by reference into this prospectus.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<table id="z2c8715b430614db9a665e8890a798500" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Offering Price</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Placement Agent&#8217;s </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Fees(1)(2)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Proceeds Before </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Expenses to Us</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 64%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Per Share&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.10</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.077</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.023</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 64%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,499,904</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">174,993.28</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,324,910.72</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<table id="za07d7c472a7b4df9b97109f4414cefb7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 94.02%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have also agreed to reimburse the placement agent for non-accountable expenses incurred by the placement agent up to an amount not to exceed $55,000. For additional information about the compensation paid to the placement agent, see &#8220;Plan of Distribution&#8221; on page S-12 of this prospectus supplement.</div>
</td>
</tr>
</table>

<div>&#160;</div>

<table id="zed115100b443420abc3a0282338aedc4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.07%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 94.93%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have also agreed to issue to the placement agent warrants with a term of five years to purchase up to 113,632 of our ordinary shares at an exercise price of $1.375 per share. For additional information about the compensation paid to the placement agent, see &#8220;Plan of Distribution&#8221; on page S-12 of this prospectus supplement.</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We expect that delivery of the ordinary shares being offered pursuant to this prospectus supplement and the accompanying prospectus will be made on or about November 22, 2017.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold 12pt/1.25 'Times New Roman', Times, serif">H.C. Wainwright &amp; Co.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">The date of this prospectus supplement is November 20, 2017.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">TABLE OF CONTENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Prospectus Supplement</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z032ead05e73c4673b49f5c1e7e6f716f" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%" cellspacing="0" cellpadding="2" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; FONT-VARIANT: normal; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"><u>Page</u></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#PROSPECTUSSUPPLEMENT">ABOUT THIS PROSPECTUS SUPPLEMENT</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-1</div>
</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#SUPPLEMENTSUMMARY">PROSPECTUS SUPPLEMENT SUMMARY</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-2</div>
</td>
</tr>

<tr style="HEIGHT: 19px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#RISKFACTORS">RISK FACTORS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-5</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#CAUTIONARYNOTE">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-6</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#USEOFPROCEEDS">US</a><a href="#USEOFPROCEEDS">E OF PROCEEDS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-7</div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#USEOFPROCEEDS">DIVIDEND POLICY</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-7</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#CAPITALIZATION">CAPITALIZATION</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-8</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#DILUTION">DILUTION</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-9</div>
</td>
</tr>

<tr style="HEIGHT: 22px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#PRICERANGE">PRICE RANGE OF OUR ORDINARY SHARES</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-10</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#DESCRIPTIONOF">DESCRIPTION OF SECURITIES</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-11</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#DESCRIPTIONOF">PRIVATE PLACEMENT TRANSACTION OF WARRANTS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-11</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#INCORPORATION">PLAN OF DISTRIBUTION</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-12</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#INCORPORATION">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-14</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#LEGALMATTERS">LEGAL MATTERS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-15</div>
</td>
</tr>

<tr style="HEIGHT: 23px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#LEGALMATTERS">EXPERTS</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-15</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 93.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#LEGALMATTERS">WHERE YOU CAN FIND MORE INFORMATION</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 6.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">S-15</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Prospectus</div>

<div style="LINE-HEIGHT: 1.25">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a id="tocpage" name="tocpage"></a><font style="TEXT-DECORATION: underline; DISPLAY: inline">Page</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: left; DISPLAY: block; TEXT-INDENT: 0pt">
<table id="z3b6c8c2b4ae4499a84bbd316dd39a79b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="3">
<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p1">ABOUT THIS PROSPECTUS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p2">PROSPECTUS SUMMARY</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">2</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p5">RISK FACTORS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p7">USE OF PROCEEDS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p72">RATIO OF EARNINGS TO FIXED CHARGES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p73">CAPITALIZATION AND INDEBTEDNESS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p74">DESCRIPTION OF ORDINARY SHARES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p75">DESCRIPTION OF WARRANTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p8">DESCRIPTION OF SUBSCRIPTION RIGHTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p9">DESCRIPTION OF UNITS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p10">PLAN OF DISTRIBUTION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">10</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p13">EXPENSES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p132">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p14">INDEMNIFICATION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p16">LEGAL MATTERS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p162">EXPERTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 94.02%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a href="#p163">WHERE YOU CAN FIND MORE INFORMATION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 94.02%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p164">ENFORCEMENT OF CIVIL LIABILITIES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5.98%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>
</table>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%1%S - %%-->
<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">ABOUT THIS <a id="PROSPECTUSSUPPLEMENT" name="PROSPECTUSSUPPLEMENT"><!--Anchor--></a>PROSPECTUS SUPPLEMENT</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">This prospectus supplement and the accompanying prospectus dated July 12, 2016 are part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. This prospectus supplement and the accompanying prospectus relate to the offer by us of our securities to certain investors. We provide information to you about this offering of our securities in two separate documents that are bound together: (1) this prospectus supplement, which describes the specific details regarding this offering; and (2) the accompanying prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus supplement or the accompanying prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. You should read this prospectus supplement, the accompanying prospectus and the documents and information incorporated by reference in this prospectus supplement and the accompanying prospectus when making your investment decision. You should also read and consider the information in the documents we have referred you to under the headings &#8220;Where You Can Find More Information; Incorporation of Certain Information by Reference.&#8221;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">You should rely only on information contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus. We have not, and the placement agent has not, authorized anyone to provide you with information that is different. We are offering to sell and seeking offers to buy our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement, the accompanying prospectus and the documents and information incorporated by reference in this prospectus supplement and the accompanying prospectus are accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement or of any sale of our securities.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 1</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">PROSPECTUS <a id="SUPPLEMENTSUMMARY" name="SUPPLEMENTSUMMARY"><!--Anchor--></a>SUPPLEMENT SUMMARY</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements incorporated by reference into this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks discussed under &#8220;Risk Factors&#8221; on page S-5 of this prospectus supplement and on page 5 of the accompanying prospectus and under similar sections in the documents we incorporate by reference into this prospectus before making an investment decision.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">Unless otherwise stated in this prospectus,</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z0f2286ec8de842ae9eb01dec3f265a1d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 7.93%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 88.82%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">references to &#8220;Check-Cap,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Check-Cap Ltd., an Israeli company, together with Check-Cap US, Inc., its U.S. subsidiary;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 7.93%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 88.82%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">references to &#8220;dollars,&#8221; &#8220;US$&#8221; or &#8220;$&#8221; refer to the legal currency of the United States; and</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 7.93%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 88.82%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the term &#8220;NIS&#8221; refers to New Israeli Shekels, the lawful currency of the State of Israel.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Overview</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We are a clinical-stage medical diagnostics company developing C-Scan&#174;, the first capsule-based system for preparation-free colorectal cancer screening.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally.&#160; This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan&#174; removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation. The C-Scan&#174; system is currently not cleared for marketing in any jurisdiction.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Since our formation, we have not generated any revenue. We do not anticipate generating any revenue for the foreseeable future and we do not yet have any specific launch dates for our product candidate. We incurred net losses of approximately $610,000 in 2014, $12.3 million in 2015 and $8.8 million in 2016. As of September&#160; 30, 2017, we had an accumulated deficit of approximately&#160;$50.8 million and a total shareholders&#8217; equity of&#160; approximately&#160;$ 5.58&#160; million.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Recent Developments</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">CE Mark Filing. </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">In September 2017</font>, we filed for the CE Mark registration of our C-Scan&#174; System, which is required for a product to be marketed in the European Union.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Corporate Information</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We are incorporated in Israel. Our principal executive offices at located at Check-Cap Building, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">29 </font>Abba Hushi Avenue, P.O. Box 1271, Isfiya, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3009000</font>, Israel. Our telephone number is +972-4-8303400 and our website is located at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>www.check-cap.com</u></font> (the information contained therein or linked thereto shall not be considered incorporated by reference in this annual report). Our U.S. agent is Puglisi &amp; Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 2</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">The Offering</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="z7569bc1c4c5d41b2a1aa1c48bfa40504" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Ordinary Shares offered</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">2,272,640 ordinary shares</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Ordinary shares to be outstanding immediately following this offering(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Approximately <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">19,259,060</font> ordinary shares</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Use of proceeds</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We estimate that the net proceeds from the sale of our securities in this offering will be approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.2</font> million, after deducting placement agent fees and expense reimbursements and our estimated expenses related to this offering. We intend to use the net proceeds from this offering to advance the ongoing clinical development of our C-Scan&#174;&#160;system, and for general corporate purposes.&#160; See &#8220;Use of Proceeds&#8221; on page S-7</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr style="HEIGHT: 103px">
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Concurrent Private Placement</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">In a concurrent private placement, we are selling to the purchasers of ordinary shares in this offering warrants to purchase up to 75% of the number of our ordinary shares purchased by such investors in this offering, or up to 1,704,480 warrants. We will receive gross proceeds from the concurrent private placement transaction solely to the extent such warrants are exercised for cash. The warrants will be exercisable on the issuance date at an exercise price of $1.25 per share and will expire <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">five years</font> from the date of issuance. At any time after the three month anniversary of the issuance date of the warrants the holder may exercise the warrants in whole or in part on a cashless basis if a registration statement and current prospectus, covering the resale of the ordinary shares issuable upon exercise of the warrants, is not available<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font> The warrants and the ordinary shares issuable upon the exercise of the warrants are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. See &#8220;Private Placement Transaction and Warrants&#8221; on page S-11 of this prospectus supplement.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Transfer Agent and Registrar</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">American Stock Transfer &amp; Trust Company</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Risk Factors</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Investment in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; on page S-5 of this prospectus supplement and on page 5 of the accompanying prospectus and under similar sections in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus supplement for a discussion of factors you should consider carefully before making an investment decision.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.38%">
<div>Nasdaq Capital Market Symbol</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 1.17%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.84%">
<div>CHEK</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt">(1)&#160;&#160;&#160;The number of ordinary shares to be outstanding after this offering is based on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,986,420</font> ordinary shares outstanding as of November 20, 2017, and excludes:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<table id="z9721446e711c48db9d40d6057ffb7c1c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 75%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9,107,464 </font>ordinary shares issuable upon the exercise of outstanding warrants with a weighted average exercise price of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$5.73</font> per ordinary share;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 3</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z2409ff6622554b22a64b2c1482fc3fbc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,522,987 </font>ordinary shares issuable upon the exercise of outstanding options with a weighted average exercise price of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$3.85</font> per ordinary share, granted under our option and equity incentive plans;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z29f296ecc18b4d0599e23c3e47070c7c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.08%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">587,763</font> restricted stock units issued to employees<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> consultants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and board members, awarded under our equity incentive plan</font>;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zdccd5282d348423da8989f9222601a46" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.08%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">612,721 </font>ordinary shares that are available for future option grants under our 2015 Equity Incentive Plan and 2015 US Sub-Plan to the 2015 Equity Incentive Plan;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z045a99690f0f4aa0b14c7473bfd90e31" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.71%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">1,704,480 ordinary shares issuable upon exercise of the warrants offered in the simultaneous private placement; and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z2b20103e96f14f56aca471644983986b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 10%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.71%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">113,632 ordinary shares issuable upon exercise of the placement agent warrants to be issued to the placement agent as compensation in connection with this offering.</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 4</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="RISKFACTORS" name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">Before deciding to invest in our securities, you should consider carefully the discussion of risks and uncertainties affecting us and our securities contained in our Annual Report on Form 20-F for the fiscal year ended December 31, 2016 and the other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. As a result of these risks and uncertainties, our business, financial condition and results of operations could be materially and adversely affected, and the value of our securities could decline. The risks and uncertainties we discuss in the documents incorporated by reference are those that we currently believe may materially affect our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may materially and adversely affect our business, financial condition and results of operations. Please also consider the following additional risks specifically pertaining to the offering.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Risks Relating to the Offering</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Since we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our management will have significant flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to influence how the proceeds are being used. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, prospects, financial condition, operating results and cash flow.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">You will experience immediate dilution in the book value per ordinary share you purchase.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Because the public offering price per share of ordinary share is expected to be substantially higher than the book value per share of our ordinary shares, you will suffer substantial dilution in the net tangible book value of the ordinary shares you purchase in this offering. Based on the public offering price of $1.10 per ordinary share, if you purchase ordinary shares in this offering, you will suffer immediate and substantial dilution of approximately <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.70</font> per share in the net tangible book value of the ordinary shares you acquire. In the event that any of the warrants issued in the concurrent private placement are exercised, you will experience additional dilution to the extent that the exercise price of those warrants is higher than the net tangible book value of our ordinary shares at the time of exercise.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Future sales of our ordinary shares may cause the prevailing market price of our shares to decrease.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The issuance and sale of additional ordinary shares or securities convertible into or exercisable for ordinary shares could reduce the prevailing market price for our ordinary shares as well as make future sales of equity securities by us less attractive or not feasible. The sale of ordinary shares issued upon the exercise of our outstanding options and warrants could further dilute the holdings of our then existing shareholders.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">There has been and may continue to be significant volatility in the volume and price of our ordinary shares on the Nasdaq Capital Market</font>.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The market price of our ordinary shares has been and may continue to be highly volatile. Factors, including timing, progress and results of current and future preclinical studies and clinical trials and our research and development programs; regulatory matters, concerns about our financial position, operations results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights, may have a significant impact on the market volume and price of our stock. Unusual trading volume in our shares occurs from time to time.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have not paid and do not intend to pay dividends on our ordinary shares. Investors in this offering may never obtain a return on their investment.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have not paid dividends on our ordinary since inception, and do not intend to pay any dividends on our ordinary shares in the foreseeable future. We intend to reinvest earnings, if any, in the development and expansion of our business. Accordingly, you will need to rely on sales of your ordinary shares after price appreciation, which may never occur, in order to realize a return on your investment.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 5</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="CAUTIONARYNOTE" name="CAUTIONARYNOTE"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">This prospectus contains statements that may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and/or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;target&#8221;, &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ought to,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potentially,&#8221; &#8220;predicts,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this prospectus supplement include, without limitation, statements relating to:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zda3131c2f25e4024a200ae6adecb1a60" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our goals, targets and strategies;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z5170b1df9c0f47368913f79eacb6b0e4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the timing and conduct of the clinical trials for our scanning system, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials, and our research and development programs;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z35d9ad845e8e4219be7e7885ecd39e00" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the clinical utility, potential advantages and timing or likelihood of regulatory filings, approvals, and licensing for the use of our system;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zbfd95585d7ca4208ac258d833541aa2a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our future business development, results of operations and financial condition;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z8b67166ea377423485625bf906db98c5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our ability to protect our intellectual property rights;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="ze60f423c726344b79b8605867b6c8bcc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr style="HEIGHT: 15px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our plans to develop, launch and commercialize our system and any future products;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z7a7daa67ee5e4b7589b5a8f1a759ead2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the timing, cost or other aspects of the commercial launch of our system;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z1b705d841baa440aa1d8d2fde91f7a46" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">market acceptance of our product;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z4eaa675a6b8d47869459e6b882a1eff2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our estimates regarding expenses, future revenues, capital requirements and our need for additional financing and strategic partnerships;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zd52919eae0be4c33928c8f02a2bff55f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.25%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our estimates regarding the market opportunity for our system;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z48a5358857bb46aabdebb771c75439e9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.25%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.27%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the impact of government laws and regulations;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z43d6550f02964dcb924e0877d171abd3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.11%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.37%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our ability to recruit and retain qualified clinical, regulatory and research and development personnel;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z3219e45135524919b484996c690bc765" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.15%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.37%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">unforeseen changes in healthcare reimbursement for any of our approved product;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z42027cc1286647ffa87aa27a1b2fe045" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.15%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.37%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">difficulties in maintaining commercial scale manufacturing capacity and capability; our ability to generate growth;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z965b493b17c44b18aa2d52360a3fd349" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.25%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.27%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our failure to comply with regulatory guidelines;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zc96809b4dbc74102b93ba7a9c2754dd2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">uncertainty in industry demand and patient wellness behavior;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z6fbdae460bdd40a0b9626cb6406f4830" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">general economic conditions and market conditions in the medical device industry;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z05892d57a9084b9eadf7c792288a01f7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">future sales of large blocks or our securities, which may adversely impact our share price;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z52981a52a7984e5881575ab5af555128" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.25%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">depth of the trading market in our securities; and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zb04c78994d2147c5856fd3e08e290fdd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 73.17%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our expectations regarding the use of proceeds of our initial public offering and the concurrent private placement<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and of</font> our August 2016<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, June 2017 and November 2017</font> registered direct <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">offerings.</font></div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus, to conform these statements to actual results or to changes in our expectations.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 6</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="USEOFPROCEEDS" name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We estimate that the net proceeds from the sale of our ordinary shares in this offering will be approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.2</font> million, after deducting placement agent fees and expense reimbursements and our estimated expenses related to this offering.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We intend to use the net proceeds from this offering to advance the ongoing clinical development of our C-Scan&#174;&#160;system, and for general corporate purposes.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">DIVIDEND POLICY</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have never declared or paid dividends on our ordinary shares and currently do not intend to pay cash dividends on our ordinary shares in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our ability to distribute dividends may be limited by future contractual obligations and&#160;restrictions under&#160;Israeli law. The Israeli Companies Law<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, 1999</font> restricts our ability to declare dividends. Unless otherwise approved by a court, we can distribute dividends only from &#8220;profits&#8221; (as defined by the Israeli Companies Law<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, 1999</font>), and only if there is no reasonable concern that the dividend distribution will prevent us from meeting our existing and foreseeable obligations as they become due. Subject to the foregoing, payment of future dividends, if any, will be at the discretion of our board of directors and will depend on various factors, such as our financial condition, operating results, current and anticipated cash needs and other business and economic factors that our board of directors may deem relevant. In addition, the payment of dividends may be subject to Israeli withholding taxes. Furthermore, if we pay a dividend out of income attributed to our Benefited Enterprise that was generated during the tax exemption period, we may be subject to tax on the grossed-up amount of such distributed income at the corporate tax rate which would have been applied to our Benefited Enterprise&#8217;s income had we not enjoyed the exemption.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 7</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="CAPITALIZATION" name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The following table sets forth our capitalization as of September 30, 2017:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z3464abb2549f48e3998435f8849d1712" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 57.4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">on an actual basis; and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z4aa05708fc3149a4804e7cd66d1ba26c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 57.4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">on an as adjusted basis to give effect to&#160;the issuance and sale of 2,272,640 ordinary shares at the offering price of $1.10 per share, after deducting placement agent fees and expenses&#160;and estimated offering expenses payable by us.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="zfca58a2afe2b4f6f9fe3042bfd179917" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">As of September 30, 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Actual</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">A</font>s<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> adjusted</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in thousands of $)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Unaudited)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Shareholders&#8217; equity:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Ordinary share capital, 57,500,000 shares authorized, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,986,051</font> shares issued, actual <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,986,051 </font>and&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">19,258,691</font> shares issued, as adjusted</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">861</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">975</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Additional Paid in Capital*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">55,507</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">57,576</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Accumulated deficit&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(50,810</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(50,810</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total shareholders&#8217; equity&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,558</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,740</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total capitalization&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,558</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,740</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">*Does not include any potential proceeds from the exercise of warrants issued in the simultaneous private placement at an exercise price of $1.25.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The number of issued and outstanding shares as of September 30, 2017 in the table excludes:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z5e9f3cd4843d4f13b1f0352126550dd9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9,107,464</font> ordinary shares issuable upon the exercise of outstanding warrants with a weighted average exercise price of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$5.73 </font>per ordinary share;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z67da40b8ce3445fd95082d3d1cf002f5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,522,987</font> ordinary shares issuable upon the exercise of outstanding options with a weighted average exercise price of $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.85</font> per ordinary share, granted under our option and equity incentive plans;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z1acc32d52853476f8a8799b3c926c852" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">587,763</font> restricted stock units issued to employees<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font>&#160;consultants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and board members, awarded under our equity incentive plan</font>;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z517b3d4a71254b34bc286fd2970c888a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">612,721</font> ordinary shares that are available for future option grants under our 2015 Equity Incentive Plan and 2015 US Sub-Plan to the 2015 Equity Incentive Plan;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z14863a3773334eb69ed1f628f3ceb1b1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">1,704,480 ordinary shares issuable upon exercise of the warrants offered in the simultaneous private placement; and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z690be9f438624b1e80cee3f6fb9c1200" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.29%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">113,632 ordinary shares issuable upon exercise of the placement agent warrants to be issued to the placement agent as compensation in connection with this offering.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 8</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="DILUTION" name="DILUTION"><!--Anchor--></a>DILUTION</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Purchasers of the ordinary shares offered by this prospectus supplement and the accompanying prospectus will suffer immediate and substantial dilution in the net tangible book value per share of our ordinary shares. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers in this offering and the net tangible book value per share of our ordinary shares immediately after this offering.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our historical net tangible book value as of September 30, 2017 was approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.58</font> million, or $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.33</font> per share, of our outstanding ordinary shares, based on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,986,051</font> ordinary shares outstanding as of September 30, 2017.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Investors participating in this offering will incur immediate and significant dilution. After giving effect to the issuance and sale in this offering of 2,272,640 ordinary shares at the public offering price of $1.10 per ordinary share, after deducting placement agent fees and expenses&#160;and estimated offering expenses payable by us and excluding the proceeds, if any, from the exercise of the warrants issued pursuant the simultaneous private placement, our as adjusted net tangible book value as of September 30, 2017 would have been approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.74</font> million, or approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.40</font> per ordinary share. This amount represents an immediate increase in net tangible book value of $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.07 </font>per ordinary share to existing shareholders and an immediate dilution in net tangible book value of $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.70</font> per ordinary share to investors purchasing ordinary shares in this offering. The following table illustrates this dilution:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="z6fed9130c53d41d09f3adcd1ae8cad24" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 85%" cellspacing="0" cellpadding="0" align="left" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Ordinary Shares</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Offering price&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.10</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Net tangible book value per share before this offering, as of September 30, 2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.33</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pro forma increase in&#160;net tangible book value per share attributable to new investors in this offering</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.07</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pro forma net tangible book value per share after the offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.40</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Dilution in pro forma tangible book value per share to new investors in this offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.70</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The number of issued and outstanding shares as of September 30, 2017 in the table excludes:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z18653fd3da8e4a1d88e1db60ada8dcac" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9,107,464</font> ordinary shares issuable upon the exercise of outstanding warrants with a weighted average exercise price of $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.73</font> per ordinary share;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="ze7a62a869ace49fd9b0b140b30350b4c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,522,987</font> ordinary shares issuable upon the exercise of outstanding options with a weighted average exercise price of $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.85</font> per ordinary share, granted under our option and equity incentive plans;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z74fb7a54a6ca42aca9958019497efdab" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">587,763</font> restricted stock units issued to employees<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font>&#160;consultants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and directors, under our equity incentive plan</font>;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z95836d77e4324732a13376fc51daad1c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">612,721</font> ordinary shares that are available for future option grants under our 2015 Equity Incentive Plan and 2015 US Sub-Plan to the 2015 Equity Incentive Plan;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zb81872791f324d3399f28dfca46f9be9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">1,704,480 ordinary shares issuable upon exercise of the warrants offered in the simultaneous private placement; and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zf9a42e82ed2f483caaa52830047645df" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr style="HEIGHT: 14px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 70.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">113,632 ordinary shares issuable upon exercise of the placement agent warrants to be issued to the placement agent as compensation in connection with this offering.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 9</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="PRICERANGE" name="PRICERANGE"><!--Anchor--></a>PRICE RANGE OF OUR ORDINARY SHARES</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our units were listed on the Nasdaq Capital Market on February 19, 2015 under the symbol &#8220;CHEKU.&#8221;&#160;&#160;Prior to that date, there was no public trading market for our securities. Our initial public offering was priced at $6.00 per unit on February 20, 2015.&#160;&#160;Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term incentive warrants. On March 18, 2015, the units separated and ceased to exist.&#160;&#160;Since such date, our ordinary shares and Series A Warrants have been listed on the Nasdaq Capital Market under the symbols &#8220;CHEK&#8221; and &#8220;CHEKW,&#8221; respectively.&#160;&#160;The following table sets forth for the periods indicated the high and low sales prices per ordinary share as reported on the Nasdaq Capital Market:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Ordinary Shares</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="z4efd539107a44b9bba2bde16638d3594" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Year Ended)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">High</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Low</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">December 31, 2015 (from March 18, 2015)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.30</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.80</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">December 31, 2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.72</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.97</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The high and low market prices of our ordinary shares for each financial quarter over the most recent full financial year and subsequent period are as set forth below:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Ordinary Shares</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="z1834930bbd0445b9bfa9e32da3616465" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Quarter Ended)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">High</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Low</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">December 31, 2017 (through November 20, 2017)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.99</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.08</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 30, 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.03</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.65</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 30, 2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.38</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.90</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">March 31, 2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.64</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.07</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">December 31, 2016&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.95</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.72</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 30, 2016&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.42</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.08</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 30, 2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.01</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.97</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">March 31, 2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.72</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.86</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">For the most recent six months, the high and low market prices of our ordinary shares are as set forth below:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="zc203ba65eaf74416b89bcb93da9d1d7f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Month Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">High</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Low</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">May 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.20</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.90</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.03</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.81</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">July 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.97</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.84</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.89</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.65</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.00</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.70</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">October 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.99</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.28</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">November 2017 (through November 20, 2017)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.52</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.08</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">On November 20, 2017, the last reported sale price of our ordinary shares on the Nasdaq Capital Market was $1.09.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 10</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="DESCRIPTIONOF" name="DESCRIPTIONOF"><!--Anchor--></a>DESCRIPTION OF SECURITIES</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We are offering 2,272,640 ordinary shares pursuant to this prospectus supplement and the accompanying prospectus. The material terms and provisions of our ordinary shares are described under the caption &#8220;Description of Ordinary Shares&#8221; on page&#160;7 of the accompanying prospectus.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">PRIVATE PLACEMENT TRANSACTION OF WARRANTS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Concurrently with the sale of ordinary shares in this offering, we also expect to issue and sell to the investors in this offering warrants to purchase up to an aggregate of 1,704,480 ordinary shares at an initial exercise price equal to $1.25 per share (the "Warrants").&#160; The exercise price is subject to certain adjustments in the event of (1)&#160;payment of an ordinary share dividend or other distribution on any class of capital stock that is payable in ordinary shares; (2)&#160;subdivisions of outstanding ordinary shares into a larger number of shares; or (3)&#160;combinations of outstanding ordinary share into a smaller number of shares.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Each Warrant shall be exercisable on the issuance date and have a term of exercise equal to five year<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">s</font> from the date of issuance. Subject to limited exceptions, a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of our ordinary shares outstanding immediately after giving effect to such exercise.&#160; At any time after the three month anniversary of the issuance date of the Warrants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> if a registration statement and current prospectus covering the resale of the ordinary shares issuable upon exercise of the Warrants is not available, the holder may exercise the Warrants in whole or in part on a cashless basis.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">If, at any time while the Warrants are outstanding, (1)&#160;we consolidate or merge with or into another entity in which the Company is not the surviving entity; (2)&#160;we sell, lease, assign, convey or otherwise transfer all or substantially all of our assets; (3)&#160;any tender offer or exchange offer (whether completed by us or a third party) is completed pursuant to which holders of a majority of our outstanding ordinary shares tender or exchange their shares for securities, cash or other property; (4)&#160;we effect any reclassification of our ordinary shares or compulsory share exchange pursuant to which outstanding ordinary share is effectively converted or exchange for other securities, cash or property or (5)&#160;any transaction is consummated whereby any person or entity acquires more than 50% of the Company's outstanding ordinary shares (each, a &#8220;Fundamental Transaction&#8221;), then upon any subsequent exercise of a Warrant, the holder thereof will have the right to receive the same amount and kind of securities, cash or other property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of shares then issuable upon exercise of the Warrant</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, if the Fundamental Transaction is not within our control, including not approved by our Board of Directors or the consideration is not in all stock of the successor entity, a holder shall only be entitled to receive from us or any successor entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of our ordinary shares in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of the ordinary shares are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">If, at any time while the Warrants are outstanding, we declare or make any dividend or other distribution of our assets (or rights to acquire our assets) to holders of our ordinary shares, by way of return of capital or otherwise, then each holder of a Warrant shall be entitled to participate in such distribution to the same extent that the holder would have participated therein if the holder had held the number of ordinary shares acquirable upon complete exercise of the Warrant immediately prior to the record date for such distribution.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">If at any time while the Warrants are outstanding we grant, issue or sell any ordinary share equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of our ordinary shares (&#8220;Purchase Rights&#8221;), then each holder of a Warrant will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder had held the number of ordinary shares acquirable upon complete exercise of the Warrant immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of ordinary shares are to be determined for the grant, issue or sale of such Purchase Rights.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The Warrants and the ordinary shares issuable upon exercise of the Warrants will be issued and sold without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the investors may exercise the Warrants and sell the underlying ordinary shares only pursuant to an effective registration statement under the Securities Act covering the resale of those shares, an exemption under Rule 144 under the Securities Act, or another applicable exemption under the Securities Act.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The Company has agreed, on or prior to December 20, 2017, to file a registration statement on Form F-1 providing for the resale by the purchasers of the warrant shares issued and issuable upon the exercise of the warrants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 11</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">PLAN OF D<a id="ISTRIBUTION" name="ISTRIBUTION"><!--Anchor--></a>ISTRIBUTION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pursuant to an engagement agreement dated October 9, 2017, we have engaged H.C. Wainwright &amp; Co., LLC, or the placement agent, to act as our exclusive placement agent in connection with this offering of our ordinary shares pursuant to this prospectus supplement and accompanying prospectus. Under the terms of the engagement agreement, the placement agent has agreed to be our exclusive placement agent, on a reasonable best efforts basis, in connection with the issuance and sale by us of our ordinary shares in this takedown from our shelf registration statement. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective investors. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our ordinary shares or the private placement warrants, and the placement agent will have no authority to bind us by virtue of the engagement agreement. Further, the placement agent does not guarantee that it will be able to raise new capital in any prospective offering.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We will enter into securities purchase agreements directly with investors in connection with this offering, and we will only sell to investors who have entered into securities purchase agreements.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We expect to deliver the ordinary shares being offered pursuant to this prospectus supplement, as well as the warrants offered in the concurrent private placement, on or about November 22, 2017, subject to customary closing conditions.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have agreed to pay the placement agent a total cash fee equal to 7% of the gross proceeds of this offering. We will also pay the placement agent $55,000 for the reimbursement of non-accountable expenses. We estimate our total expenses associated with the offering, excluding placement agent fees and expenses, will be approximately $90,000.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have also agreed to issue to the placement agent, warrants to purchase up to 113,632 ordinary shares which is equal to 5.0% of the aggregate number of ordinary shares placed in the offering.&#160; The placement agent warrants will have an exercise price of $1.375 per share, which is equal to 125% of the offering price per share in this offering, and will have a term of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">five </font>year<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">s</font>.&#160; The placement agent warrants will have substantially the same terms as the Warrants being sold to the investors in the simultaneous private placement transaction. Pursuant to FINRA Rule 5110(g), the placement agent warrants and any shares issued upon exercise of the placement agent warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of&#160; commencement of sales of this offering, except the transfer of any security: (i) by operation of law or by reason of our reorganization; (ii) to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii) if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The following table shows per share and total cash placement agent&#8217;s fees we will pay to the placement agent in connection with the sale of the ordinary shares pursuant to this prospectus supplement and the accompanying prospectus assuming the purchase of all of the ordinary shares offered hereby:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="z6dde9d2ccb7b4fe298b4726ac52095e3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 85%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Per Ordinary Share</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Total</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Public offering price&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.10</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,499,904</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Placement agent fees&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0.077</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">174,993.28</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Proceeds, before expenses, to us&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.023</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,324,910.72</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">After deducting certain fees due to the placement agent and expenses&#160;and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.2</font> million.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 12</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Right of First Refusal</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">If, within the nine-month period following the closing of this offering, we or </font>any of our subsidiaries (a) decides to dispose of or acquire business units or acquire any of our outstanding securities or make any exchange or tender offer or enter into a merger, consolidation or other business combination or any recapitalization, reorganization, restructuring or other similar transaction, including, without limitation, an extraordinary dividend or distributions or a spin-off or split-off, and we decide to retain a financial advisor for such transaction, the placement agent (or any affiliate designated by the placement agent) shall have the right to act as our exclusive financial advisor for any such transaction; or (b) decides to finance or refinance any indebtedness using a manager or agent, placement agent (or any affiliate designated by placement agent) shall have the right to act as sole book-runner, sole manager, sole placement agent or sole agent with respect to such financing or refinancing; or (c) decides to raise funds by means of a public offering or a private placement of equity or debt securities using an underwriter or placement agent other than any Strategic Transaction (as defined below) or Equity Line Transaction (as defined below), the placement agent (or any affiliate designated by the placement agent) shall have the right to act as sole book-running manager, sole underwriter or sole placement agent for such financing. If the placement agent or one of its affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions for customary fees for transactions of similar size and nature and the provisions of the engagement letter between the placement agent and us, including indemnification, which are appropriate to such a transaction.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8220;Strategic Transaction&#8221; means an acquisition or strategic transaction which is not with a potential investor introduced by the placement agent to us and is approved by a majority of our disinterested directors; provided that any such transaction shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with our business and shall provide us additional benefits in addition to the investment of funds, but shall not include a transaction in which we are issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities (other than Equity Line Transaction). &#8220; Equity Line Transaction&#8221; means (i) an offering of securities including ordinary shares at a purchase price, conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of the ordinary shares at any time after the initial issuance of such debt or equity securities, or (ii) a transaction whereby we may issue securities at a future determined price rather than a fixed price. &#8220;Non-US Offering Transaction&#8221; means any offering of our securities that takes place wholly outside of the United States of America.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Tail Financing Payments</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have agreed that the placement agent shall be entitled to compensation, with respect to any public or private offering or other financing or capital-raising transaction of any kind other than a Strategic Transaction, an Equity Line Financing or a Non-US Offering Transaction (&#8220;Tail Financing&#8221;) to the extent that such financing or capital is provided to the Company by investors whom the placement agent had contacted during the term of its engagement&#160; or introduced to the Company during the term of the placement agent&#8217;s engagement by the Company, other than the entities that were specified on a list delivered by the Company to the placement agent&#160; if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of the placement agent&#8217;s engagement by the Company.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Indemnification</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have agreed to indemnify the placement agent and specified other persons against certain civil liabilities, including liabilities under the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and to contribute to payments that the placement agent may be required to make in respect of such liabilities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it, and any profit realized on the resale of the ordinary shares and warrants sold by it while acting as principal, might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the Securities Act and the Securities Exchange Act of 1934, as amended, or Exchange Act, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of ordinary shares and warrants by the placement agent acting as principal. Under these rules and regulations, the placement agent:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9679;&#160; &#160; &#160;&#160; may not engage in any stabilization activity in connection with our securities; and</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9679;&#160; &#160; &#160;&#160; may not bid for or purchase any of our securities, or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution in the securities offered by this prospectus supplement.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 13</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Relationships</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The placement agent and its affiliates may have provided us and our affiliates in the past and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, the placement agent and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.&#160;However, except as disclosed in this prospectus supplement, we have no present arrangements with the placement agent for any further services.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The placement agent acted as our exclusive placement agent in connection with our registered direct offering we consummated in June 2017, for which it received compensation.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Listing</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;CHEK.&#8221;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="INCORPORATION" name="INCORPORATION"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this prospectus:</div>

<div style="LINE-HEIGHT: 1.25">
<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zde0feaff412e44d39340fa771ce6776b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 68.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">our Annual Report on Form 20-F for the fiscal year ended December 31, 2016, filed with the SEC on March 9, 2017;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z97b6d7d9555e487ba0d517e5fa362c0b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 68.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our Current Reports on Form 6-K and Form 6-K/A filed with the SEC on March 10, 2017, May 9, 2017, May 18, 2017 , May 24, 2017, May 30, 2017, June 2, 2017, June 15, 2017, August 10, 2017, September 27, 2017, October 10, 2017, October 24, 2017, October 25, 2017, November 6, 2017 and November 20, 2017;</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="ze36780ebd0c84f3c8163516ddfdb1620" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 68.94%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">the description of our ordinary shares contained in our Registration Statement on Form F-1, as amended, under the Securities Act, as originally filed with the SEC on December 23, 2014 (Registration No. 333- 201250) under the heading &#8220;Description of Securities&#8221; and as incorporated into our Registration Statement on Form 8-A12B, filed with the SEC February 11, 2015;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zde348be071ab45abaaa442a462934017" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 68.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">any Form 20-F or 6-K filed with the SEC after the date of this prospectus and prior to the termination of this offering of securities (except to the extent such reports are furnished but not filed with the SEC); and</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z8f50e8fdd50645f2a32bcaee16985626" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 3%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 68.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">any Report on Form 6-K submitted to the SEC after the date of this prospectus and prior to the termination of this offering of securities, but only to the extent that the forms expressly state that we incorporate them by reference in this prospectus.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Potential investors, including any beneficial owner, may obtain a copy of any of the documents summarized herein (subject to certain restrictions because of the confidential nature of the subject matter) or any of our SEC filings incorporated by reference herein without charge by written or oral request directed to Lior Torem, Chief Financial Officer; at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3009000</font>, Israel; Our telephone number is +972-4-8303400.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in a subsequently filed document incorporated by reference herein, modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this prospectus.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 14</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="LEGALMATTERS" name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The validity of the ordinary shares and legal matters as to Israeli law has been passed upon for us by Fischer Behar Chen Well Orion &amp; Co<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> Tel Aviv, Israel.&#160; Legal matters as to United States and New York law has been passed upon for us by Loeb &amp; Loeb LLP, New York, New York.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">EXPERTS</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The financial statements as of December 31, 2016 and 2015 and for each of the years in the two-year period ended December 31, 2016 have been audited by Brightman Almagor Zohar &amp; Co., a member firm of Deloitte Touche Tohmatsu, or Deloitte, an independent registered public accounting firm and have been incorporated by reference herein and in the registration statement in reliance on the report of Deloitte incorporated by reference herein and upon the authority of said firm as experts in accounting and auditing. The address of Brightman Almagor Zohar &amp; Co., a member firm of Deloitte, is 1 Azrieli Center, Tel Aviv, 67021, Israel.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">WHERE YOU CAN FIND MORE INFORMATION</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">We have filed with the SEC a registration statement on Form F-3 under the Securities Act with respect to the offer and sale of securities pursuant to this prospectus. This prospectus, filed as a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules thereto in accordance with the rules and regulations of the SEC and no reference is hereby made to such omitted information. Statements made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to the registration statement are summaries of all of the material terms of such contract, agreement or document, but do not repeat all of their terms. Reference is made to each such exhibit for a more complete description of the matters involved and such statements shall be deemed qualified in their entirety by such reference. We are subject to periodic reporting and other information requirements of the Exchange Act as applicable to foreign private issuers and accordingly we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. In addition, we intend to publish our results on a quarterly basis as press releases distributed pursuant to the rules and regulations of the stock exchange on which our ordinary shares are listed.&#160;&#160;Press releases relating to financial results and material events will also be furnished to the SEC on Form 6-K. As we are a foreign private issuer, we are exempt from some of the Exchange Act reporting requirements, namely, the rules prescribing the furnishing and content of proxy statements to shareholders and Section 16 short swing profit reporting for our officers and directors and for holders of more than 10% of our shares. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. You may read and copy any document we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on the public reference rooms and their copy charges. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding issuers, such as us, who file electronically with the SEC. The address of that website is <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>http://www.sec.gov.</u></font></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">S - 15</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div>&#160;</div>

<div style="FONT-WEIGHT: bold">PROSPECTUS</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader">
<div style="LINE-HEIGHT: 1.25">
<div style="TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">$50,000,000</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><img src="logo.jpg"></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">CHECK-CAP LTD.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Ordinary Shares</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Subscription Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Units</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We may offer ordinary shares, par value NIS 0.20 per share, par value NIS 0.20 per share, warrants, subscription rights and/or units from time to time. When we decide to sell securities, we will provide specific terms of the offered securities, including the offering prices of the securities, in a prospectus supplement. The securities offered by the Registrant pursuant to this prospectus will have an aggregate public offering price of up to $50,000,000.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">The securities covered by this prospectus may be offered and sold from time to time in one or more offerings, which may be through one or more underwriters, dealers and agents, or directly to the purchasers. The names of any underwriters, dealers or agents, if any, will be included in a supplement to this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">This prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered. The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. A prospectus supplement may also add, update or change information contained in this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Our ordinary shares are traded on the NASDAQ Capital Market under the symbol &#8220;CHEK&#8221;.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">The aggregate market value of our outstanding ordinary shares held by non-affiliates is approximately $24,960,332, which was calculated based on 9,600,124&#160;&#160;ordinary shares held by non-affiliates as of July, 11, 2016, and a price per share of $2.60, the last reported sale price per share of our ordinary shares on the Nasdaq Capital Market on May 13, 2016.&#160;&#160;As of the date hereof, we have not offered any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date hereof. </div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Pursuant to General Instruction I.B.5 of Form F-3, as long as the aggregate market value of our ordinary shares held by non-affiliates remains below $75.0 million, we will not, during any 12 calendar month period, sell the securities in a public primary offering with a value exceeding more than one-third of the aggregate market value of our ordinary shares held by non-affiliates.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Our principal executive offices are located at Check-Cap Building, Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel.&#160;&#160;Our telephone number is +972-4-8303400. Our website address is www.check-cap.com.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Investing in our securities involves risks. You should consider carefully the risk factors referred to in this prospectus on page&#160;5 and in the applicable supplement to this prospectus before investing in any securities that may be offered.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Neither the Securities and Exchange Commission nor any state or other securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Prospectus dated July&#160;12, 2016</div>

<div style="TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%"></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a id="tocheading" name="tocheading"></a>TABLE OF CONTENTS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a id="tocpage" name="tocpage"></a><font style="TEXT-DECORATION: underline; DISPLAY: inline">Page</font></div>
</div>

<div style="TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt">
<div style="TEXT-ALIGN: left">
<table id="zdc65f0658ec5475f998c4b0f904ecf41" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="3">
<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p1">ABOUT THIS PROSPECTUS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p2">PROSPECTUS SUMMARY</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">2</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p5">RISK FACTORS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p7">USE OF PROCEEDS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p72">RATIO OF EARNINGS TO FIXED CHARGES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p73">CAPITALIZATION AND INDEBTEDNESS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p74">DESCRIPTION OF ORDINARY SHARES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p75">DESCRIPTION OF WARRANTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p8">DESCRIPTION OF SUBSCRIPTION RIGHTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p9">DESCRIPTION OF UNITS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p10">PLAN OF DISTRIBUTION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">10</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p13">EXPENSES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p132">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p14">INDEMNIFICATION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p16">LEGAL MATTERS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p162">EXPERTS</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 62%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a href="#p163">WHERE YOU CAN FIND MORE INFORMATION</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 62%" valign="top" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 50.4pt; TEXT-INDENT: 0pt"><a href="#p164">ENFORCEMENT OF CIVIL LIABILITIES</a></div>
</td>
<td style="TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 12%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" valign="top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">16</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"></div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="PAGE-BREAK-AFTER: always; MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%"></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"></div>

<br>
<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><a id="p1" name="p1">ABOUT THIS PROSPECTUS</a></font></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer from time to time securities having a maximum aggregate offering price of $50,000,000. Each time we offer securities, we will prepare and file with the SEC a prospectus supplement that describes the specific amounts, prices and terms of the securities we offer. The prospectus supplement also may add, update or change information contained in this prospectus or the documents incorporated herein by reference. You should read carefully both this prospectus and any prospectus supplement together with additional information described below under the caption &#8220;Where You Can Find More Information.&#8221;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">This prospectus does not contain all the information provided in the registration statement we filed with the SEC. For further information about us or our securities offered hereby, you should refer to that registration statement, which you can obtain from the SEC as described below under &#8220;Where You Can Find More Information.&#8221;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">You should rely only on the information contained or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement, as well as information we have previously filed with the SEC and incorporated by reference, is accurate as of the date of those documents only. Our business, financial condition, results of operations and prospects may have changed since those dates.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">We may sell securities through underwriters or dealers, through agents, directly to purchasers or through any combination of these methods. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will prepare and file with the SEC each time we offer securities, will set forth the names of any underwriters, agents or others involved in the sale of securities, and any applicable fee, commission or discount arrangements with them.&#160;&#160;See &#8220;Plan of Distribution.&#8221;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%"></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt"><a id="p2" name="p2">PROSPECTUS SUMMARY</a></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements incorporated by reference into this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks discussed under &#8220;Risk Factors&#8221; on page&#160;5&#160;before making an investment decision.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Unless otherwise stated in this prospectus,</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z6d22a0c55ef14bfebb82665c741cdf09" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-STYLE: italic; TEXT-ALIGN: left">references to &#8220;Check-Cap,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Check-Cap Ltd., an Israeli company, together with Check-Cap US, Inc., its U.S. subsidiary;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z80d4c7259195454e9952fdd6507a1bb4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-STYLE: italic; TEXT-ALIGN: left">references to &#8220;dollars,&#8221; &#8220;US$&#8221; or &#8220;$&#8221; refer to the legal currency of the United States; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z9fb626baa619494091e2e5be931eb88a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-STYLE: italic; TEXT-ALIGN: left">the term &#8220;NIS&#8221; refers to New Israeli Shekels, the lawful currency of the State of Israel.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Overview</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We are a clinical stage medical diagnostics company engaged in the development of an ingestible capsule system that utilizes ultra low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. While CRC is the second leading cause of death from cancer for both sexes combined in the United States and is largely preventable with early detection, according to 2013 National Health Interview Survey, only 58% of Americans between the ages of 50 to 75 reported being current with CRC screening recommendations. Unlike other screening modalities that are designed to generate structural information of the internal colon for the detection of colonic polyps and CRC, such as optical colonoscopy, computed tomographic colonography, or CTC, and other capsule-based technologies, our system is designed to be ingested without any cathartic preparation of the colon, and to travel through the gastrointestinal tract naturally while the patient continues his or her normal daily routine. Furthermore, unlike existing CRC imaging modalities currently on the market, all of which require the patient to fast for several hours prior to administration, the procedure for the Check-Cap system is designed to enable patients to continue eating normally. Our system is comprised of three main components: (1) ingestible scanning capsule; (2) Capsule Positioning System, or CPS, a recorder worn on the patient&#8217;s back; and (3) a PC-based work station for data reconstruction and image processing. We believe that this solution will be attractive to both physicians and patients, with the potential to increase the number of people undergoing CRC screening.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Our scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Unlike other CRC screening methods, this process should not disrupt a patient&#8217;s normal activities or require fasting. Our scanning capsule employs ultra low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. As such, we believe that patients using our system will not be required to undergo any prior bowel preparation. The Radiation Safety Division of the Soreq Nuclear Research Center found, as set forth in its report of November 2010 that was prepared at our request and based on the information provided by us and the relevant methods and principles known at such time, or the Report, that the radiation dose to the patient in the proposed screening procedure utilizing the scanning device developed by us at that time in routine operation and normal conditions is low relative to the radiation dose involved in conventional imaging procedures using X-rays (such as fluoroscopy and CT) and is also low when compared to the radiation dose involved in established screening procedures such as mammography, all as more fully described in the Report.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Our scanning capsule is being designed to transmit position, motility, and the data it collects to an external data recorder and capsule positioning system or CPS, that will be worn by the patient. The external data recorder is being designed to enable the transfer of the data to our PC-based work station with viewer software application to allow physicians to analyze the data collected by our scanning capsule. The CPS is being designed to provide the physician with accurate localization data aligned with a reconstructed image. We intend for physicians to be able to review the colon&#8217;s inner images at any location at any time, in less time than is required to perform an optical colonoscopy.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">2</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Colonic polyps are tissue growths that occur on the lining of the colon. Polyps in the colon are extremely common, and certain types of polyps can become cancerous over time. In the event that polyps are identified through our system, the patient may be advised to undergo a subsequent traditional colonoscopy procedure to examine, remove and biopsy the polyps. For those patients who require a subsequent polypectomy, concerns regarding pain, discomfort and embarrassment may still remain with respect to the subsequent polypectomy. We do not, however, believe that these concerns will make the use of our system any less attractive to physicians and patients. Although patients who are initially screened utilizing a traditional colonoscopy could avoid the need for a second procedure if polyps are discovered because they could undergo a polypectomy during the initial screening, if necessary, we believe that our system will still be attractive to physicians and patients as a majority of patients who are screened will not require a subsequent polypectomy. Published data from a multi-center CT colonography screening study of 2,531 asymptomatic adults showed that if all patients with a lesion measuring 5mm or more on CT colonography were referred for colonoscopy, the colonoscopy-referral rate would have been 17%.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">A clinical proof-of-concept study, which was based on a 10-case study conducted at Tel Aviv Sourasky Medical Center in Israel and used a prior version of our system, did not identify any material safety or feasibility issues. The study demonstrated the applicability of our system to the human colon, generating images taken in the colon without any prior bowel preparation. All subjects ingested the capsule easily with smooth passage within the designated transit time, on average, within two to three days. There were no reported device-related adverse events. Mild effects on bowel movements were noted, which were determined to be related to the contrast agent and passed within one to two days after the capsule was excreted.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Another objective of the 10-case study was to estimate total radiation exposure for each case study. This was calculated using standard established factors for calculating effective radiation exposure, such as the duration of the capsule inside the body, and was based on the activity of the radiation source inside the scanning capsule and radiation energy, both of which were measured for each case study. The average calculated exposure for the entire procedure in the 10-case study, from ingestion of the capsule to excretion, was 0.03 mSv (STD 0.007 mSv). This level of radiation exposure is similar to a single chest X-ray (approximately 0.06mSv) and two orders of magnitude less than a CTC.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">The 10-case clinical proof-of-concept study focused on assessing the safety and feasibility of our system.&#160;The 10-case study was the first phase of a multi-center, prospective clinical feasibility study to establish the safety, functionality and preliminary efficacy of our system in patients eligible for CRC screening, by comparing results from the clinical feasibility study with those from non-invasive, low-sensitivity FOBTs and FITs, as well as from optical colonoscopies. The feasibility study is designed allow for recruitment of 100 subjects. The study is being conducted at multiple centers in Israel, with the potential to be conducted at a single site in the Netherlands. The clinical feasibility study will evaluate the image resolution generated by the capsule in an a human colon without cathartic preparation, will assess polyp imaging in various shapes and in different segments of the colon and will evaluate the safety of the device in terms of total and segmental transit time and analyze the effects of the presence of polyps and variable colon dimensions on these parameters. The study will seek to create a clinical atlas of images that will enable comparisons between images acquired by different CRC screening modalities. During the feasibility study we will collect data about the overall imaging of the colon&#8217;s internal surfaces during the passage of the capsule to support the development of a correlation map of polyps identified through our imaging system with polyps imaged by optical colonoscopy and CTC.&#160;Additionally, the feasibility study will measure total radiation exposure and the distribution of contrast material within the colon.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">A preliminary analysis conducted on the first 54 capsules swallowed by participants enrolled in the multi-center, prospective clinical feasibility study showed 53 of 54 capsules swallowed and naturally eliminated without major or minor side effects after <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">66 &#177;37 </font>hours. Image reconstructions allowed 3D views of the colonic wall and lumen with the typical contour of different segments (hepatic flexure, triangular shape of the transverse colon). Both pedunculated and sessile polyps were detected in several patients and validated later by colonoscopy.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">To date, we have achieved key product development milestones, including the demonstrated ability of our system to reconstruct the human colon and to identify polyps, and design freeze of the current version of our system. Following the successful completion of the multi-center, prospective clinical feasibility study and design release and transfer to manufacturing phases, we plan to submit during the first half of 2017, a request for CE marking for the marketing and sale of our capsule in the European Union. We expect to perform post-marketing studies in Europe following CE marking for the purpose of collecting additional clinical data to support market adoption. Subject to regulatory approvals, available capital, and engagement with strategic partners, we anticipate launching our system commercially in Europe during 2018.</div>
</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">3</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We plan to conduct a pre-submission meeting with the FDA, during 2016. Subject to this meeting, we plan subsequently to submit a request for the approval of an investigational device exemption, or IDE, for a pilot study in the United States. Subject to successful completion of the pilot study and receipt of required approvals, we plan to initiate during 2018, a pivotal study in the United States to (i) demonstrate device safety&#160;as evidenced by a lack of device-related serious adverse events; and (ii) provide efficacy data concerning our system&#8217;s performance.&#160;We anticipate that FDA approval for the pivotal study will be subject to our providing sufficient clinical data from previous clinical studies, which may include the multi-center, prospective clinical feasibility study and U.S. pilot study. However, there can be no assurance that the FDA will grant approval for the pilot and/or pivotal studies to be conducted in the United States.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We also intend to pursue clinical trials for regulatory approvals in Japan and China in parallel to the U.S. pivotal study, subject to available capital and engagement with strategic partners. Pivotal studies are expected, among other things, to compare polyps identified by our system with the polyps identified by traditional optical colonoscopy.&#160;These clinical findings may be analyzed in comparison with results obtained from FOBTs and FITs.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Following and subject to the successful completion of our pivotal trial, our current strategy is to submit a direct de novo reclassification petition, which we anticipate submitting in 2019, for initial FDA clearance for the marketing of our system in the United States. Direct de novo reclassification typically takes at least 9 to 12 months from filing to clearance. If the FDA determines that our system is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA process. The PMA pathway is much more costly and uncertain than the 510(k) clearance process or de novo reclassification, and generally takes at least 12 to 18 months, or even longer, from the time the application is filed with FDA to ultimate approval.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Timelines expectations are based on our current estimations and expectations, which may continue to be updated along with our progress, which is subject to the occurrence of various factors and future events, among others, the satisfactory completion of system&#8217;s development process, testing, and integration, which may require more time than currently expected, as well as the success of our clinical trials and the completion of our required regulatory approvals, all of which are uncertain as of the date of this Prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We have submitted patent applications covering our technology in the United States, member states of the European Patent Organisation, Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and South Korea. We have been granted patents for our core patent by the U.S. Patent and Trademark Office as well as from the European Patent Office, Australia, China, Hong Kong, Israel, India and Japan. We also filed patent applications describing the use of our technology in several other medical applications.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Since our formation, we have not generated any revenue. We do not anticipate generating any revenue for the foreseeable future and we do not yet have any specific launch dates for our product. We incurred net losses of $3.4 million in 2013, $610,000 in 2014 and $12.3 million in 2015. As of March 31, 2016, we had an accumulated deficit of $36.8 million and a total shareholders&#8217; equity of $10.3 million.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Check-Cap&#8217;s principal executive offices at Check-Cap Building, Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel. Our telephone number is +972-4-8303400 and our website is located at <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.check-cap.com</font> (the information contained therein or linked thereto shall not be considered incorporated by reference in this annual report). Our U.S. agent is Puglisi &amp; Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">The Securities We May Offer</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We may use this prospectus to offer up to $50,000,000 of:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="za545c0f8cdb749e5b096962cf113367e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">ordinary shares;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zfe0d00f5194d430390e61e6470b2793d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">warrants;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="za8b31c0549934243935ee33a48f337fa" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">subscription rights; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zba7d6dd895264344b299849c83039554" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">units, which may consist of any combination of the above securities.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">We may also offer securities of the types listed above that are convertible or exchangeable into one or more of the securities listed above.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">4</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;<a id="P5" name="P5">RISK FACTORS</a></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">An investment in our securities involves risk. Before you invest in securities issued by us, you should carefully consider the risks involved. Accordingly, you should carefully consider:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z257975c76ef94062a0cb68b82546df5b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the information contained in or incorporated by reference into this prospectus;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z66524e31a4b04437bb6357dbb6d10ba0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the information contained in or incorporated by reference into any prospectus supplement relating to specific offerings of securities;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z45e9c3512345470baa400ec990bfce32" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the risks described in our Annual Report on Form 20-F for our fiscal year ended December 31, 2015 on file with Securities and Exchange Commission (the &#8220;SEC&#8221;), which is incorporated by reference into this prospectus; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z0bedc28999864b35a4af6a8bfb88a056" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">other risks and other information that may be contained in, or incorporated by reference from, other filings we make with the SEC, including in any prospectus supplement relating to specific offerings of securities.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The discussion of risks related to our business contained in or incorporated by reference into this prospectus or into any prospectus supplement comprises material risks of which we are aware. If any of the events or developments described actually occurs, our business, financial condition or results of operations would likely suffer.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">5</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">CAUTIONARY NOTE REG<a id="P6" name="P6">AR</a>DING FORWARD-LOOKING STATEMENTS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">This prospectus contains statements that may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and/or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;target&#8221;, &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ought to,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potentially,&#8221; &#8220;predicts,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this Annual Report include, without limitation, statements relating to:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z96080573440a477b8ef875c95d37cfa1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our goals, targets&#160;and strategies;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z71eb906fba2946ca8510883632aa8f18" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the timing and conduct of the clinical trials for our scanning system, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials, and our research and development programs;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4d61383e21954813b22566d56847a502" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our system;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zdb801ce82cd34f3ebcf0577ccf964a74" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our future business development, results of operations and financial condition;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zfc2faeec222846fb962ff251bfb6c959" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our ability to protect our intellectual property rights;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze56fbe73f0af4b32b8ebd1ad0cf2759a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our plans to develop, launch and commercialize our system and any future products;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zee9261c9d90d498b93d266b29140eda5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the timing, cost or other aspects of the commercial launch of our system;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z73a6076b07fd4c12807d36ced4dce760" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">market acceptance of our product;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4bcf5b3a8b334726833adf6446dac2ab" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our estimates regarding expenses, future revenues, capital requirements and our need for additional financing and strategic partnerships;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z191e9272fa1e467f9381acac05a6288a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our estimates regarding the market opportunity for our system;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z44090599692f4eb7900156a32dae8c16" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the impact of government laws and regulations;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="za4b02fe6fccb46a6b8371169dcdb8268" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our ability to recruit and retain qualified clinical, regulatory and research and development personnel;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zf31b4ef90322442986fccdca13d717bd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">unforeseen changes in healthcare reimbursement for any of our approved product;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zc67dbc270fbf4ec58ef2311a7fabc223" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">difficulties in maintaining commercial scale manufacturing capacity and capability; our ability to generate growth;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z0bac5c3b42404b7d9a466c448039236d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our failure to comply with regulatory guidelines;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z35c32479f77641649f1efc1f60eb78e2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">uncertainty in industry demand and patient wellness behavior;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z73d6a663af514787979a9c70f9d13ef4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">general economic conditions and market conditions in the medical device industry;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z86b50bb7f12e488891c51e3aa9b763e9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">future sales of large blocks or our securities, which may adversely impact our share price;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z7c7d967ff85845e0958179bb3e8a2f2e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">depth of the trading market in our securities; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze66225f497ad472eb42d76aadbe78424" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our expectations regarding the use of proceeds of our initial public offering and the concurrent private placement.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus, to conform these statements to actual results or to changes in our expectations.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">6</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><a id="p7" name="p7">USE OF PROCEEDS</a></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Unless the applicable prospectus supplement states otherwise, the net proceeds from the sale of securities offered by the Company will be used for general corporate purposes, which may include additions to working capital, operating expenses, research and developments expenses, and other general corporate purposes. The precise amount, use and timing of the application of such proceeds will depend upon our funding requirements and the availability and cost of other capital. Additional information on the use of net proceeds from an offering of securities covered by this prospectus may be set forth in the prospectus supplement relating to the specific offering.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">RATIO OF EARNINGS TO F<a id="P72" name="P72">IXE</a>D CHARGES</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Not applicable to smaller reporting companies.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">CAPITALIZATION AND IN<a id="P73" name="P73">DEBT</a>EDNESS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Our capitalization and indebtedness will be set forth in a prospectus supplement to this prospectus or in a report on Form 6-K subsequently furnished to the SEC and specifically incorporated herein by reference.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">DESCRIPTION OF ORDINARY S<a id="P74" name="P74">HAR</a>ES</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">A description of our ordinary shares can be found in our Registration Statement on Form F-1, as amended, under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as originally filed with the SEC on December 23, 2014 (Registration No. 333-201250) under the heading &#8220;Description of Securities&#8221; and as incorporated into the Company&#8217;s Form 8-A, filed with the SEC on February 11, 2015, which description is incorporated by reference herein.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">DESCRIPTION OF WA<a id="P75" name="P75">RR</a>ANTS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The following summary of certain provisions of the warrants does not purport to be complete and is subject to, and qualified in its entirety by reference to, the provisions of the warrant agreement that will be filed with the SEC in connection with the offering of such warrants.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">General</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may issue warrants to purchase ordinary shares. Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent. The warrant agent will act solely as our agent and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The applicable prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z325e586f3d3847e4a74d8ee4d62ac448" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the title of such warrants;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z7fa38ad004dc413cbcfe8623c7347f6f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the aggregate number of such warrants;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zd4ff81a41707448eb1a65b156a3762d3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the price or prices at which such warrants will be issued and exercised;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z37a2b4a4d1324f39ba741a6654674059" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the currency or currencies in which the price of such warrants will be payable;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zfd8385c4910847aeae4c4b55888e99d0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the securities purchasable upon exercise of such warrants;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z9ebc442959bc470497c2cb0e36a4cf55" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the date on which the right to exercise such warrants shall commence and the date on which such right shall expire;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z6a451946f5b64368bd1eb51c182167e3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">7</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div>
<table id="z1485255fc72f447d9b1a11710b230592" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">if applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with each such security;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zc6f74c6a7780440aae271eeb4a6a718f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">if applicable, the date on and after which such warrants and the related securities will be separately transferable;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z85f27419c2f44cdd8ae5362756ff3917" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">information with respect to book-entry procedures, if any;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z2d5a20a020cf4be9ac531d939ade64f7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">any material United States federal and Israel income tax consequences;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4f7c82a5a74940e68860ae8107002668" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the anti-dilution provisions of the warrants, if any; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zff1c1128934347d49a11901feeed67a3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">any other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt">Amendments and Supplements to Warrant Agreement</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We and the warrant agent may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the warrants issued thereunder to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">DESCRIPTION OF SUB<a id="P8" name="P8">SCR</a>IPTION RIGHTS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The following summary of certain provisions of the subscription rights does not purport to be complete and is subject to, and qualified in its entirety by reference to, the provisions of the certificate evidencing the subscription rights that will be filed with the SEC in connection with the offering of such subscription rights.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">General</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may issue subscription rights to purchase ordinary shares. Subscription rights may be issued independently or together with any other offered security and may or may not be transferable by the person purchasing or receiving the subscription rights. In connection with any subscription rights offering to our shareholders, we may enter into a standby underwriting arrangement with one or more underwriters pursuant to which such underwriters will purchase any offered securities remaining unsubscribed for after such subscription rights offering. In connection with a subscription rights offering to our shareholders, we will distribute certificates evidencing the subscription rights and a prospectus supplement to our shareholders on the record date that we set for receiving subscription rights in such subscription rights offering.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The applicable prospectus supplement will describe the following terms of subscription rights in respect of which this prospectus is being delivered:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4344ecaf77554b7f92dc4e8edae8edf7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the title of such subscription rights;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zda37e9eaf5824d47a3e69d638294bfaf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the securities for which such subscription rights are exercisable;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z99b60cbadb2f46ec81621423d842598b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the exercise price for such subscription rights;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="za48642f6406441159a8c755e66e77616" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the number of such subscription rights issued to each shareholder;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z65eba0df0f834b2595dd3997de315d26" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the extent to which such subscription rights are transferable;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4d19de1174574e9f9d9e5886d9bf24f6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">if applicable, a discussion of the material United States federal and Israel income tax considerations applicable to the issuance or exercise of such subscription rights;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zd5af498f13634fa8a9ae8638cd84c237" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the date on which the right to exercise such subscription rights shall commence, and the date on which such rights shall expire (subject to any extension);</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z02fce25412c24ccea4a8e6710a52e606" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the extent to which such subscription rights include an over-subscription privilege with respect to unsubscribed securities;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z9ff6a5a85ffc4756b5538741a2a7740d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">if applicable, the material terms of any standby underwriting or other purchase arrangement that we may enter into in connection with the subscription rights offering; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z82469d7f798143919712b2bf1abea334" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">any other terms of such subscription rights, including terms, procedures and limitations relating to the exchange and exercise of such subscription rights.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">8</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Exercise of Subscription Rights</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Each subscription right will entitle the holder of the subscription right to purchase for cash such amount of ordinary shares at such exercise price as shall be set forth in, or be determinable as set forth in, the prospectus supplement relating to the subscription rights offered thereby. Subscription rights may be exercised at any time up to the close of business on the expiration date for such subscription rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised subscription rights will become void.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Subscription rights may be exercised as set forth in the prospectus supplement relating to the subscription rights offered thereby. Upon receipt of payment and the subscription rights certificate properly completed and duly executed at the corporate trust office of the subscription rights agent or any other office indicated in the prospectus supplement, we will forward, as soon as practicable, the ordinary shares purchasable upon such exercise. We may determine to offer any unsubscribed offered securities directly to persons other than shareholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as set forth in the applicable prospectus supplement.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;DESCRIPTION OF <a id="P9" name="P9">UNITS</a></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">As specified in the applicable prospectus supplement, we may issue units consisting of one or more ordinary shares, warrants or any combination of such securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">9</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt">&#160;PLAN OF DIS<a id="P10" name="P10">TRIB</a>UTION</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may offer and sell, from time to time, some or all of the securities covered by this prospectus up to an aggregate public offering price of $50,000,000.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Securities covered by this prospectus may be sold from time to time, in one or more transactions, at market prices prevailing at the time of sale, at prices related to market prices, at a fixed price or prices subject to change, at varying prices determined at the time of sale or at negotiated prices. The securities being offered by this prospectus may be sold:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z9222a9be2a4f416684d4a9f562246c32" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">through agents;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z62d28cfe3e214ff3ae784e793a822904" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">to or through one or more underwriters on a firm commitment or agency basis;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z86089e673d444ffc91254e2a517c3197" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">through put or call option transactions relating to the securities;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4d584da243084e838286d86f5a80875c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">through broker-dealers (acting as agent or principal);</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z8c6a6329faa3421886ac8752a2ea4c6b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">directly to purchasers, through a specific bidding or auction process, on a negotiated basis or otherwise;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zdac96488740d4618a2a24ca857797e4e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">through any other method permitted pursuant to applicable law; or</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zf6e6c4ebb09a4beeb63227de81d507b4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">through a combination of any such methods of sale.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">At any time a particular offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required, will be distributed which will set forth the aggregate amount of securities covered by this prospectus being offered and the terms of the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions and other items constituting compensation and any discounts, commissions or concessions allowed or re-allowed or paid to dealers. Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the securities covered by this prospectus. In order to comply with the securities laws of certain states, if applicable, the securities sold under this prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from registration or qualification requirements is available and is complied with.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The distribution of securities may be effected from time to time in one or more transactions, including block transactions and transactions on the NASDAQ Market Capital or any other organized market where the securities may be traded. The securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in the form of discounts, concessions or commissions to be received from us or from the purchasers of the securities. Any dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If any such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Agents may from time to time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any agent involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">If underwriters are used in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell the securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">10</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">If a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others. These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities. To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding or auction process, if used.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Agents, underwriters and dealers may be entitled, under agreements which may be entered into, indemnification by us against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us and the Selling Shareholders to payments they may be required to make in respect of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our subsidiaries or their affiliates.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the securities laws of some jurisdictions, the securities offered by this prospectus may be sold in those jurisdictions only through registered or licensed brokers or dealers.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Any person participating in the distribution of securities registered under the registration statement that includes this prospectus will be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation M, which may limit the timing of purchases and sales of any of our securities by that person. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of our securities to engage in market-making activities with respect to our securities. These restrictions may affect the marketability of our securities and the ability of any person or entity to engage in market-making activities with respect to our securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids that stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain the price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zcd60fc28bca94feaa985b8b58d1a60f4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">A stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining the price of a security.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zc3e35b19a330473e8a43417a79da6ba8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">A syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in connection with the offering.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z0fe90dc2b3e641469534251402687970" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">A penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in connection with the offering when offered securities originally sold by the syndicate member are purchased in syndicate covering transactions.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">These transactions may be effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted for trading on that automated quotation system, or in the over-the-counter market or otherwise.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">11</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">If so indicated in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase offered securities from us at the public offering price set forth in such prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject only to those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation of such contracts.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">In addition, ordinary shares may be issued upon conversion of or in exchange for other securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Each series of offered securities, other than the ordinary shares which are listed on NASDAQ Capital Market, will be a new issue of securities and will have no established trading market. Any underwriters to whom offered securities are sold for public offering may make a market in such offered securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The offered securities may or may not be listed on a national securities exchange. No assurance can be given that there will be a market for the offered securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Any securities that qualify for sale pursuant to Rule 144 or Regulation S under the Securities Act may be sold under Rule 144 or Regulation S rather than pursuant to this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">To the extent that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a distribution agreement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution agreement, we will offer and sell our ordinary shares to or through one or more underwriters or agents, which may act on an agency basis or on a principal basis. During the term of any such agreement, we may sell ordinary shares on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. The distribution agreement will provide that any ordinary shares sold will be sold at prices related to the then prevailing market prices for our ordinary shares. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time and will be described in a prospectus supplement. Pursuant to the terms of the distribution agreement, we also may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of our ordinary shares or other securities. The terms of each such distribution agreement will be set forth in more detail in a prospectus supplement to this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">In connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant to which we receive our outstanding securities in consideration for the securities being offered to the public for cash. In connection with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements to close out any related open borrowings of securities.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">One or more firms, referred to as &#8220;remarketing firms,&#8221; may also offer or sell the securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for us. These remarketing firms will offer or sell the securities in accordance with a redemption or repayment pursuant to the terms of the securities. The prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act and may be customers of, engage in transactions with or perform services for us in the ordinary course of business.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may enter into derivative transactions with third parties or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties (or affiliates of such third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of shares, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such third parties) in such sale transactions will be underwriters and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment).</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus. Such financial institution or third party may transfer its short position to investors in our securities or in connection with a simultaneous offering of other securities offered by this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">12</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt">EX<a id="P13" name="P13">PENS</a>ES</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, all of which shall be borne by the Company. All of such fees and expenses, except for the SEC registration fee and FINRA fees, are estimated.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table id="z76f7468aee324691bb8563705f64d6d4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr bgcolor="#cceeff">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">SEC registration fee</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">8,824.20</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr bgcolor="white">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">FINRA fees</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="#cceeff">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Transfer agent&#8217;s fees and expenses</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="white">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Legal fees and expenses</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="#cceeff">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Printing fees and expenses</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="white">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Accounting fees and expenses</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="#cceeff">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Miscellaneous fees and expenses</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>

<tr bgcolor="white">
<td style="WIDTH: 88%" valign="bottom" align="left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Total</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; WIDTH: 1%" valign="bottom" align="left">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%" valign="bottom">&#160;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" nowrap="nowrap">*</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">* To be provided by a prospectus supplement or as an exhibit to a Report on Form 6-K that is incorporated by reference into this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">INCORPORATION OF CERTAIN INFO<a id="P132" name="P132">RM</a>ATION BY REFERENCE</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this prospectus:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z38efe52e73014a35a2eca4b7a3d1356b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">our Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on March 15, 2016;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze26d12e4d25e46e2a6c7d49be79bbfe1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">Amendment No.1 on Form 20-F/A to our Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on April 15, 2016;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z5817e1b52aa14f55b09c4b41d56db822" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">Our Current Reports on Form 6-K filed with the SEC on March 15, 2016, March 18, 2016, May 17, 2016, May 19, 2016, May 25, 2016 and June 3, 2016;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zdc7e1d5c6f4a40f683d95e1140420355" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the description of our ordinary shares contained in our Registration Statement on Form F-1, as amended, under the Securities Act, as originally filed with the SEC on December 23, 2014 (Registration No. 333- 201250) under the heading &#8220;Description of Securities&#8221; and as incorporated into our Registration Statement on Form 8-A12B, filed with the SEC February 11, 2015;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="za996c14832ae40e595b22666874846b2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">any Form 20-F or 6-K filed with the SEC after the date of this prospectus and prior to the termination of this offering of securities (except to the extent such reports are furnished but not filed with the SEC); and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze44623d209bf4108bf5e2ec697362074" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">any Report on Form 6-K submitted to the SEC after the date of this prospectus and prior to the termination of this offering of securities, but only to the extent that the forms expressly state that we incorporate them by reference in this prospectus.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Potential investors, including any beneficial owner, may obtain a copy of any of the documents summarized herein (subject to certain restrictions because of the confidential nature of the subject matter) or any of our SEC filings incorporated by reference herein without charge by written or oral request directed to Lior Torem, Chief Financial Officer; at Check-Cap Building, Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel; Our telephone number is +972-4-8303400.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in a subsequently filed document incorporated by reference herein, modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this prospectus.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">13</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">INDEMN<a id="P14" name="P14">IFIC</a>ATION</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the Israeli Companies Law, 1999 (the &#8220;Israeli Companies Law&#8221;) a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended articles of association include such a provision to the fullest extent permitted by law. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or other distribution to shareholders.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the Israeli Companies Law and the Israeli Securities Law, 1968 (the &#8220;Securities Law&#8221;) a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of any such event or following an event, provided its articles of association include a provision authorizing such indemnification:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the Israeli Companies Law and the Israeli Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a financial liability imposed on the office holder in favor of a third party; and</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder or certain compensation payments to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Securities Law.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">14</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the Israeli Companies Law, a company may not indemnify, exculpate or enter into an insurance contract which would provide coverage for any monetary liability incurred as a result of any of the following:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an act or omission committed with intent to derive illegal personal benefit; or</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: symbol, serif; DISPLAY: inline">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a fine, monetary sanction or forfeit levied against the office holder.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to the chief executive officer or a director or under certain circumstances, also by the shareholders.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Our amended articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Israeli Companies Law and Israeli Securities Law. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We have entered into indemnification and exculpation agreements with each of our current officers and directors exculpating them from a breach of their duty of care to us to the fullest extent permitted by the Israeli Companies Law and undertaking to indemnify them to the fullest extent permitted by the Israeli Companies Law and the Israeli Securities Law, to the extent that these liabilities are not covered by insurance. This indemnification is limited to events determined as foreseeable by our board of directors based on our activities, as set forth in the indemnification agreements. Under such indemnification agreements, the maximum aggregate amount of indemnification that we may pay to any and all of our currently serving or future officers and directors together may not exceed the higher of $5 million and 25% of our shareholders equity according to our most recent financial statements at the time of payment.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">15</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt">&#160;LEGAL M<a id="P16" name="P16">ATT</a>ERS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The validity of the warrants, subscription rights and units and legal matters as to United States and New York law has been passed upon for us by Loeb &amp; Loeb LLP. The validity of the ordinary shares and legal matters as to Israeli law has been passed upon for us by Fischer Behar Chen Well Orion &amp; Co., Tel Aviv, Israel.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;EX<a id="P162" name="P162">P</a>ERTS</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">The financial statements as of December 31, 2015 and 2014 and for each of the years in the two-year period ended December 31, 2015 have been audited by Brightman Almagor Zohar &amp; Co., a member firm of Deloitte Touche Tohmatsu, or Deloitte, an independent registered public accounting firm and have been incorporated by reference herein and in the registration statement in reliance on the report of Deloitte incorporated by reference herein and upon the authority of said firm as experts in accounting and auditing. The address of Brightman Almagor Zohar &amp; Co., a member firm of Deloitte, is 1 Azrieli Center, Tel Aviv, 67021, Israel.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;WHERE YOU CAN FIND M<a id="P163" name="P163">OR</a>E INFORMATION</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We have filed with the SEC a registration statement on Form F-3 under the Securities Act with respect to the offer and sale of securities pursuant to this prospectus. This prospectus, filed as a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules thereto in accordance with the rules and regulations of the SEC and no reference is hereby made to such omitted information. Statements made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to the registration statement are summaries of all of the material terms of such contract, agreement or document, but do not repeat all of their terms. Reference is made to each such exhibit for a more complete description of the matters involved and such statements shall be deemed qualified in their entirety by such reference. We are subject to periodic reporting and other information requirements of the Exchange Act as applicable to foreign private issuers and accordingly we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. In addition, we intend to publish our results on a quarterly basis as press releases distributed pursuant to the rules and regulations of the stock exchange on which our ordinary shares are listed.&#160;&#160;Press releases relating to financial results and material events will also be furnished to the SEC on Form 6-K. As we are a foreign private issuer, we are exempt from some of the Exchange Act reporting requirements, namely, the rules prescribing the furnishing and content of proxy statements to shareholders and Section 16 short swing profit reporting for our officers and directors and for holders of more than 10% of our shares. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. You may read and copy any document we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on the public reference rooms and their copy charges. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding issuers, such as us, who file electronically with the SEC. The address of that website is <font style="TEXT-DECORATION: underline; DISPLAY: inline">http://www.sec.gov.</font></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;ENFORCEMENT OF CIVIL LI<a id="P164" name="P164">ABI</a>LITIES</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We are incorporated under the laws of the State of Israel. All but one of our current executive officers, the Israeli experts and two of our serving directors listed reside in Israel, and substantially all of our assets and a substantial portion of the assets of these persons are located in Israel. Therefore, service of process upon us and upon our directors and officers, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets, and a substantial portion of those of our directors and officers who reside outside the United States and the Israeli experts named herein, are located outside the United States, any judgment obtained in the United States against us or any of these persons may not be collectible within the United States.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We have appointed Puglisi &amp; Associates as our agent to receive service of process in any action against us in any United States federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. The address of Puglisi &amp; Associates is 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">16</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; WIDTH: 100%"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">We have been informed by our legal counsel in Israel, Fischer Behar Chen Well Orion &amp; Co., that there is doubt as to the enforceability of civil liabilities under U.S. securities laws pursuant to original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the grounds that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses, which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law.</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Subject to certain time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter, including a judgment based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z8df48f7e64604f348e5dc716691aefd8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z2c1f432d80aa4e1cbb9fb63f64a24beb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment may no longer be appealed;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4f1655aa525447119461c6a87aa57fa7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z920103cf09e54ae2b2f51659b73e34ee" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment is executory in the state in which it was given.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Even if such conditions are met, an Israeli court may not declare a foreign civil judgment enforceable if:</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="zabc04136147b4dc09a63e613c6268539" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze29e5825e5064175b71f978868ffec59" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z06abb52b77ff475fb78bd9b920f502d6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment was obtained by fraud;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z82e34f7d19664357b2e959f0b90a27a4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="ze0b600a1591049ae9d8286c94070ac0d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z1f4d8bc9d4304c90994bc07827938a88" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table id="z4b2e45b23b3d470d91fa40655befc0b6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'times new roman', times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"></div>
</td>
<td style="WIDTH: 18pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#183;</div>
</td>
<td>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt">Foreign judgments enforced by Israeli courts generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to render judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at that time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; WIDTH: 100%"></div>

<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; WIDTH: 100%">17</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" size="3" noshade="noshade">
</div>
</div>
</div>
</div>
</div>
</div>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK-CAP LTD.</div>

<div style="FONT-SIZE: 14pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2,272,640 Ordinary Shares</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zd2ee5dc0f2ad4a8997c8a61088723cbb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">PROSPECTUS SUPPLEMENT</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z77a0716e343d4a17b1ea38bbe36b33eb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/1.25 'Times New Roman', Times, serif">H.C. Wainwright &amp; Co.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="z6982441e445b4ff6aa9ca268cca3cff3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">November 20, 2017</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal"></font>&#160;</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!W8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6BDP$I:2EI( HHHJ
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M***A@+124M4F 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****
M@8M%)2U28@HHHHN 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:*3 2BBBI&%%%%"
M6BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE2P"BBBD,**** "BBB
M@ I:2EJD(****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "44M)4M %+1130!1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $HI:2IL 4444["N%%%+22&%%%%4 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !24M% #:*6BF2%+112*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG^]1_;I_O5/*&QZ2-8']ZC^V!_>KS?\ MT_WJ/[=/]_]::5AGI']L#^]3AK
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M6 ]+&L+_ 'J7^V%_O5YG_;Q_O4G]OG^]2<0L>E'6!_>IO]L#^]7F_P#;Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!(F:2D/6E%*P!BEI:::JP"TF*!3Z5@&T$T&FDU206 TFW-+3U%#*1&$IX6I
MM&*AL=Q!2,>*6F.>*S;+BKE.8\TZT3>XIDHR:T-+A+2#CO7+.1T):&]I5CN9
M>*]-\.6&TKQ7-:%I^[;Q7I>B6.W;Q6$I$\MV=/IEOMB7BMF-<5!9Q!8Q5O%<
M\I7+M8<*6FBGUFRUJ1D4 4_%&*BY8 4ZDI:H!K57DJ=C5>1A2; J2U1E-7)C
M5&7K2W @:FA>:DHQ0 @%2 4W%2**8";:3%2]J8U) ,I*4T50!0**44,!0*"M
M/%!J.H$9I*4T@JT E+110 N*7;2K3^U2P(L4E/-,JD E+10:8"BE"T@J05#
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MG TVBJ >33329HHL 4F:6C%2V 4HI**I /W4A--S118 I,TM&*3 2E%&**$
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M/(U49WJ0*DTO-5S)FB<DFH5I] )J4=*1:<!Q20!12XI*L HHI*A@+2@TE%4
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MJ:H!'7BJK=:MN>*K..: %CJY#UJFG%6XC0!IPGBK:FJ,+5;4U-P)A2T@I:H
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I***D!:***H
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M <!3\<4U:?GBI8$9%-IYIE4@"BB@T7 44\"F"I :3 0BHS4A-,-" 2BBBG<
M%. IHIXI,!Q'%,(I^>*8U) -[T4=Z*JX!2BD[THH8#P*0BG TA-2!&:*#15
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M77%BL<>HYJ=*=)#L/2HPV#6T61)%@4C#BA#FI"N:V1BU8JE>:!Q4[)4+#%,
MS24W-*#4L+!2BBE J0N/44I% -!--,!AIP%-[U(HJKB$(IAJ8CBH'-2-"BEQ
M3%-/SQ64QD34Z,9-,<\U:LX]["N>1HD:&GP9D7CO7JGA2WY3BN'TFQW.O%>H
M^&K39MXKFJ&D%J>@Z9!B%>*UE7%5;!<0K5[%<C-T@I:2EJ2D%%%% PHHII-
M$<IXK,N&ZU?E;BLNX/)H3&BLS9-1D4$\TFZAL&+BGBFCFG=*!7)0*1A4?F8H
M\S- "&DIW6G!:I(!F**?MI,55@%"YI2G%2(*>5XHY0*3#%-%3NE1A:5BA113
ML4TT.)(HI<4P&G@U-AH0BFU*%S08^*+ R,44-Q30V:JQ-QW>G 4@%2 5-@;$
M(IAJ4BFE:.429%25,$IWE4K%%?%.%3>53&7%.P"44POBE#9II%"TE!IA:AHF
MP^@4U3FI M2  4I%. H(J22,TE*:!5I%"4M%-S5\HKCQ3L4U34H'%2XB9$12
M 5,4II7%.P[B 4C4A;%)NS4M"N)WIX%- IXI6!L"*8>M/-,-4D"8E+29HIV'
M<*>M,IP.*EH9)CBHVIV^DZT@&4\"C%&<4F)B&FCK2,U(&YJ;C1,!010AXI6H
M3 C[THIII0:JXF/II-+FF&A @/--Q030#3&2(.:NV_4520\U=@H U(>E356B
M/%3@T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI*3 *6DI:$ 44
M44P"D-+24"9#(>*S;IOE-:4O2LF\/RFMJ9E(X3Q0_P CUXKX@?\ ?-]:]D\3
MGY'KQ?7_ /7-]:ZHHS9SQ;FE!S49ZT]:WB(>%S4R+BD1:EQBMD9R%SQ4$C5*
M34+\U:)0U3S4ZBH%'-6%Z4,&Q#Q3,T]J9BI)N.%!H%!IW)&@\U.G-0 <U.AQ
M1<JX]EXJK(,5;8\57D%3(:96-6+5]KU PI8FPU8LT3.OTN]*%>:[S1;_ ';>
M:\KLYL$<UU^CWNTKS4,T3/9M*G#*.:Z*"08%>;Z3J@"K\U=79ZB& ^:N>:*3
M.E=@5K.G7.:<ESN7K2_>J(JQ391:WW=J@DT\-VK7$5.,7%7S$'-2Z2&_AJ$:
M*N?NUTS(*14&:=P:.?71E'\-._LH#^&NC$0QTI&A'I0IDV,6"P"MTK9MH-JC
MBD6( U:486E.5RDBE=\*:Y+6G_=-73ZC+M4UP^MW/R-S13 \R\4-EFKA0?WQ
M^M=AXCEW,W-<<@S-^-:6+Z'0Z6?F6O3/#C'*UYOI2?,M>F^&XN5IO0Q>YZ/I
MI_=+6I_#5'3HOW2UI%/EK&30[,YS6/NM7G&N-]ZO2M83Y6KS?6T^]6E,B1YS
MK!Y:N7;_ %A^M=5K"\M7,,/WA^M;%QV)XAQ3V'%)%TI[4[$ME=Z@8\U8>H2N
M318:+EB>177Z5]Y:Y2R3D5UNE+\RU+B-GHN@?PUZ#8#]VM<'X?3.VO0K&/\
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MP]JHI5Z&@5R_$>*L+5>(<5944Q(>****104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444E $4OW:QKT_*:V)ONUBWOW36U,RDSS_ ,3'
MY'KQO7_]:WUKV+Q,?E>O&]?/[UOK79$R.=;[U.3K3"?FIR5M$EER,<5(:BC:
MGYS6J(8QJC(J4BF&M"6(!4@I@IXH9#%I**3-22+2445/4!:<#BF9HS5V DW4
MAZ4S-+NJ)(M$4@J$'#5,_-18YJ+&B9<@DQBMRQN]F.:YM&Q5R"?;WK.2*/0=
M.U0@CYJ[+3-3SCYJ\CM+W:1S74Z;J>,?-631:/7K.]#*.:V8)0PZUYMI^K#
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MBE,Q5LI3#'4\I297&<4C,:F*4TI5)%7(,G-681FF>7S4T8Q3Y1W+"QC%!C%
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M/%L:FQOM-44F=AI$P##FO1=$G&%YKR73+G#CFO0-%O/N\U#%)'J5A*"!S6_
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MGZ4MI'MQ2:F,VYJDP/&_%88R/7$) S2=*]&\1VV^1N*YZUTW=(.*:+Z%?3K
MLR_+7=Z+I>0N5J#2](Y4[:[C2M-V@<5HM#,;!I2[!\M3C2US]VNBALP$'%2?
M9.>E5SA8P8M,7^[2W&EKY?W:Z..U]J6>V_=]*.="L>9:IIH&[Y:XC5;';NXK
MU[4[+(;BN#UNRP&XK5:@>5:A#M8\5E-D&NGU6##GBL"6/FFT");"0B05W.CS
M'Y:X>R3]Y79Z0.5J&BFST;1I2=M=SIY)05PFAKDK7H&GI^[%83$C3CZ55OL;
M35H?**S-0FPIK*PV<OJ^W:U>7^(S][%>A:Q<<-S7FVO/NW5K&)*W. O&/G-3
M(2<BI;M,RFHXAAA6\%8MG3Z/&&9<UZ#I-FK*O%<%HGWEKTK1?NK6C(L=!9:8
MC <5J#2$V_=J734R!6ZL'R]*PE(9R\FDI_=K/GTE?[M=G) /2JSV>[M638SS
M^[TH8/RUSM]I?7Y:]3N=.RO2N?OM,X/RTDP/)=0L-N>*YB\@*D\5ZCJ^GX#<
M5PNIVNUCQ6R8CDY 0:FM)"'I]S%@U7AX>HDM31;'9:5<D%>:]$T&YR5YKRG3
MYL,.:[_0;GE>:=M"3UO3I@8AS6H#FN7TNXS&O-=%;MN J+#N2L*KN*ML.*JO
MUK*2*3(\4X4E**S&2J:":8#1FH8(.]2+4=.!I6+)#49IV:::I(8R@4&D!YJK
M!8E7K5R"JB5<AHL%C2BZ5,*KQ'BIQ2$.HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *2BBF*XTU!,ORFK)J&4?*::9#1PGB9?W;UX
MMXA'[UOK7MWB=?W;UXIXB'[UOK7539DT<=,.351NM7)QR:J-UKIB9LCIZT8I
MP%;Q8AXHH%.Q6J)8"I!TIH6GTR!C"H\<U*:9BF*X"GTE%-$,7-,-&:*H:1&P
MIA!J?;FG>72+3(4%3K1LQ13);N.I"::332:FPT#5$U2$TF,TF:)D0SFI5S0$
MIX6IL#9&V:9@YJSLS2&+BBPTR%3BI :C?Y:8'JD%B?-,:G*<TNVJ$5V!J(@Y
MJX8Z;Y5%AJ0R(<U<0<5 J8J4-@520G*Y+Q2<&H3)0'S3$2%14;#%2 Y%(PJ&
M20Y-.!H*T8K-B8AIM/--Q0A)@*6DZ4N: $-%.Q1C%4BD--1L:D-1D515QH-2
M TP"GBF)CA3A2**=C%($.%(<4PMBDWT!84T8HZTX"@8PBD[U(149J6*X]34N
MX8JKOQ1YM(M(F8U$W- ;-+C-(1#MYIZBI?+IP2@;8T4\4F*3-#1#8I-1FG4A
M%"0KC:*#0*8"U(M(%IX%- Q3TJ)JD)J,U8K@M28&*B!IX:@8-4;9J7K32M %
M<YIO-3E*/+HL4I$:YJ=*:$Q2]*E@V2T$U'NHW5)(,:B8FI.M(5H8)D!)I5)J
M3RZ4)4VU+OH(,TO-."T\)5F=R+)I-U2.N*@/6BQ2U)EYJ9!44?-65&*M&<B9
M0,5#-BG;L"JTTE0PCJ1Y&ZK,72L_?\U6X6XI7-7$DFZ5FR_>K1DY%4W3+5$D
M5'0CC!JVD9:FPQ<ULV-IYC 8HV&S/6R=^@I_]F2?W:[G3]#\T#Y:UU\-9'W/
MTK*4@2/+6TN3^[4#Z;)_=KUEO#/'W/TJ!_#/^Q^E1>Y:T/*1ILN?NU(--D_N
MUZ;_ ,(SS]S]*>/#7^Q^E!39YA_9DG]VE&F2?W:]1'AG_8_2G#PQ_L?I4M@>
M7C3)/[M._LR3^[7I_P#PC./X/TIK>'/]C]*FX-'E[:<X'W:JR6[)VKT^Y\/[
M4)VUS&I:9Y1/RTDR4CD>0:<":L30;6/%0[<5TTF#'+4@%,6I5%=*9FQ,4G2I
M0M-<8H%8A)J-C3F-,J) D,-"#YJ>5H0?-7/(HWM*CRPKO]$@^9>*XO18]S+7
MI&AP?=XK"1I$[O08\*M=G#]P5RVC1[0M=5%]T5PSW-X[#Z6BBH'86BBBD4%-
M;I3J:_2@"G,:H2M5Z:J$U0P*DAYIHI)#S2IS510#Q3Q2A>*0\5LD1(D0TVY8
M"(TS?BJM[/B)OI6B1DSD-?G"[N:\RUFYRS<UV?B6[QNYKS#4[O=(PS6RV),7
M4'W,:J0KEJEG;<U/MTY%1RZFE]#6TV++K7H6AV88+Q7%Z3%F1:]0\/6V0O%:
M$(Z33+$ +Q74V=NJJ.*HV5OM4<5JQ?**REJ46 H ICGBD+U$[U(T12-S1&<F
MHW-(K8J6QEPHI6J-Q;*V>*L"7BFD[JAL1DO9J#TIGV< ]*U63-1F*IN%BK$F
M*@OUW1$5H;,57N4W+BJ3$>=:Q9EW;BJ-AIO[P?+797ECO8\4RTTW:PXK6)0_
M3-/  ^6NHLK95 XJO9VNT#BM6%=M62D6T0!:?L6H@^!1YG-3RL;+*(*)D&RF
MQR4Z5ODJ&FF!@:A$,-Q7":]$N&KO-0<8-<)KSC#5UT]B&>7ZRH#M7-3 9KI=
M:;YVKEYVYK<1-:8WUUVE,,K7%6LGSUU>ER\K6<@:/4- ()6O1=/ \D5YCX>D
MY2O2],;,0KFF@1?<<5AZGG:U;Y7(K(U*+*FLTRF>=ZP6PU>?ZQGYJ]*UB'AJ
M\[UM,;JV@S-;G#W0'F&H$(W5->'$AJHK_-70F:K4ZW1#\RUZ7HG1:\QT$Y=:
M]1T(?*M)DL[S2APM=$H&P5S^F< 5MM)A*Y)[@AKE<TJ!35":XPW6I()\FI>P
MRY) I7I6/>68(/%;2ON6HI8MPJ$QGG&M6/#<5YSK%GAFXKV?6+3*MQ7G>LV/
M+<5O!C1Y7?0$$\5E!=KUUNJ6NTMQ7,S)M<UI8=RU:2;6%=KH=QRO->?Q/M85
MUVB3_,O-(&>MZ1/E5YKL+%\@5Y[HTWRKS7<:;)E14,S-QONU4D'-6LY6H'%9
M,N)7Q13R*;63*$I11BBHL4D.HH%. IE""G4N*:::&AC4P=:D- 7FF421U=BJ
MHE7(: +L=3BH8QQ4XJ2!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %)2T4 -HI:2F2+3)!\IIU(_W: .*\3+E'KQ;Q%&?,;ZU[AXB3*/7
MD'B&#YVXKII,SDCSJY7!-4&/-;%_'M)K$D.&-=43%HD!IXJ!6J9#FMHDV) *
M>* .*#Q6R9+'4=J:#3^U60QAI,TCG%1;N:!<MR:D-*O(H8<4T*Q&33A33UIR
MT7&R1:E&*AS2[Z$R"1L5$U+NS330P&$TW-.-,HN6A14BU&*<#4C)>*.*9NI<
MTP)EQ3FQMJ$-07XI 5Y^M0+G-3OS3 O--(T4M"1*F%0KQ3P:HALEXI<"H]U&
MZJ1(XU&QI2U,-4 QC0IYI2* *3*3T)T-.S42FEW5+$/--I-U&:R8F%%!-,S4
MDV%- HZTN*I,H>*0TW-&:H8TTE/IIIIBN)BE H%. IW"XX4K=*;2$U+&B)SS
M2+G-.(S2 515R1:D%1 U(IJ6)L<:A;I4I-1-2)3(7J/)S4I&:;MIFJ>@Y*G6
MH5&*E4TF0V3@#%!Q30>*0M2"X&HS2DTE,5P%.[4VC--$B&E I:.E TQXI:9N
MI0:0,#3#3S49JA(2G"D%. IW'<>M.J/-*&HN [%&*3-!-.Y*W%.*C:EW4G6I
M90RC-*13>]2.Y(M/J-:?FBY'4=@4E-W4N:"APJ1<8J+-+NQ1<D)>E56ZU.S9
MJ(CFJ1<="6*K.>*J(<5+OJB9*XYVJK*:E+9J%AFI:''0KC.ZKD)XJOMYJ=.!
M69M?0G8Y%0D<TXGBF$T-DEF' (KHM'VF09KEEDP:W-(N,2CFHD4D>M:%#&RK
MD5UT-E&RCY:X;P_=_*O-=[83!P*YIZ%I$G]F1D?=J)]*3^[6_#&&6GM![5BJ
MEF6XG,_V2G]VE&E)_=KH_LWM2_9O:J]JA*)SZZ4G]VG_ -EI_=K>\C':CR?:
MH=0?*8!TM/[M0MI2?W:Z;R,]J:;;VJ74+Y3B[W2E\L_+7!Z[I7WL+7LMS9Y0
M\5R>K:4'#?+3C,EQ/"K[3V1FXK%F38:]/UK2-FX[:\[U:+RG;BNJ$C-JYG*>
M:F0U3#\U81JZH2%:Q:6FR=*%;BFR'BJ<A%1SS2+2.>:5:RE(0_'%+&/GI*?$
M/G%8M@D=;H$>66O4M#M_E7BO./#<>76O6]#M_P!VO%83-$=1ID>T+70Q_=%9
M-E'M K67I7%/<Z([#J6DHJ!W%HHHH&%,<\4M1N>*FX%:8UGS'K5J=ZSY7S2L
M.Q5D/-/B-1MUI4.*M"9='2D84Q&J=5R*UBR64WR*RM0D(B;Z5LW"X!KGM3;$
M;5M$RD>;>)Y3\W->97TA,K<]Z]&\2G):O-KT?O6^M;(@J9R:OVJ9(K/'6M>P
M3)% '1Z-#^\7BO5O#D0VK7G.C0_.M>H: FU5J9#1V," (/I4AXI(?N"E;I4%
MHC9\5&9,U',^*KB3YJEA8LGFF'-/CYIS+Q63&0ACFID-0D<T]3BL[CL3\4$"
MH]U&_F@8,*AD3(JP.::R\4T*QG/ ">E206ZYZ5(XYJ:W'(K5.PK%F*' Z5+L
MQ5B)/EH=0*M2'8J,V*@:;!J2X(6LFXN I/-;(+&M'= =Z)KY0AYKF9-1V]ZS
MKO6<*?FJ)1U(9K:CJ*8;FN&UN^5@W-1:EK?7YJY#4=6+[OFK:"LB#-U><,[5
MS<[9-6[VZWL>:S7;)K4I(FMB=]=1I><K7,VBY>NMTJ/E:SF#/0O#N<K7I^E?
MZH5YOX>CY6O3-,7$0KFDQ&H.E9NH8VFKS-@5EW\GRFL[:C./UA1AJ\TU_C=7
MI.KM\K5YGXA;[U:Q)L<#?']Z:I+]ZK-Z<RM4,2Y85M$M*QU7A\?.M>K:$/D6
MO+] 3YUKU31!A%JV#5SMM.. *U9&^3\*QK%L 5K?>6N>:%8S9\[J?;Y!JP\&
M[M2"+;6+8[%V%^*L@@BLY7Q4XEXI6N.Q2U-%937":Q; AN*[J\;<#7*ZK%E&
MK6&@SRO6H0N[BN)O!AS7H/B!,;J\^O?]8U:D/<H9P]=+HLF&6N9_BK=TMMI6
MI:*OH>HZ+/PO-=_I+Y"UY;HL_*UZ3H;Y5:ED'6IRM-84^(?(*5AQ6<BDRH]1
M9YJ67BJQ;FL66B84N*8IJ4"I-$(!4BT!:#Q0 IZ5&U+FD- #:<*8W%"MS5(I
M%A15R$55B&:O0K0,N1CBIJBCZ5+4D!1124K@+1113 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I*6DH$Q*1ONTZD/2F)(YG7(]R-7ENOVV2QQ
M7KNJQ[E:O/M;M,AN*WID3/'M7AVEJY2;[YKN_$$&PMQ7"W'^M-=4618:E6HZ
MAC7-6%&*Z(F;)@>*:QI,\4TFM(D,4&I >*A!IV>*VB0QLAJ$=:E;FF@<T-#3
MT)HZ>W2F)3S00V0D<TX4I% I"; TPU)3<4A(0&G9IM&:8P--Q3\9I"* N-HH
MI0*0PIV:,4E,:89H.:4<TNVAC8RC%*1252)#%%.Q2$4"N)FBBG 4QC:*4BDI
MIB#%&*<*"*387&TF:#2BI;& IPHQ2UFV)L0TSO3S28J=P0@IQIM&:8 :444N
M*JX7%II%/I,4(5Q@IXI,4F:H>XIIE.ZTN* N,HQ2F@4[C 4X48I.E(5[CB:8
M:7-+B@-B/%&*>13:!W#%.% %*12"XN>*:31FCK2$)3J,4M -B&F]Z?28H0)@
M*4TW-&:H!*<*,4G2@!Q/%,-+FE H#8:*?VI,4F: W T@I:7% "YI#29HH 2G
M"C%)TH#<4TW%+FEQ0&P"EHQ14"&&E%+BDZ4QW%S2$TF:=BA(!E%.Q25HAW"B
ME I<47%<;FDQ2FE6DV,3;1C%28XII%24A*0TM+BH9:(&)S6AILI605185+;M
ML:H96QZ5H=\%V\UZ+H]^&V\UXAI^H>61S7?:#JF2OS5E-712D>S6,RM&*T!@
MUR>DWNZ->:Z2WEW 5P3@T;)W+804NP4Y>12UC<I(C*"F[*EI,4[A8:%%+M%&
M:4&D4B.2(%3Q61>6@8'BMP\BJ\T60:<7831YGXAT\;&PM>/^(;!A(V!WKZ%U
MJSWHW%>7:_I.2QVUUTY7,MCQ][=D:D4X-=!J=CY1;BN>?Y9,5TQG835RW'S2
MR+Q1;\BII$XK3FN9-&;(.::#BII5YJNQQ4L$3 YJQ;IEQ5.)LFM:RCW,*Q9:
M1V_A>'+)Q7L.B0?NEXKS'PM!\R<5[!HT.(5XK"<K%)&Q;I@"KHZ5"BX%3"N:
M3NS5!2T45(TA:2EHJ64,-0R'BI6JO(>*@:11N#6?)UK0FYJC(*I,96-*M(U.
M051+)H^M78^E546K*G JXF9!==#7+ZJ?D:NFNCP:YC5?]6U=$")'F/B0\M7G
M-ZW[QOK7H/B4XW5YM>O^];ZUJA)$2GYJWM+&2M<XC?-73:1R5HN-H[G1H^5K
MTC1$P%K@=%3[M>BZ,GRK4R8D=+'P@I'<8I.B56>3G%0:6&S?-581G=5V-=]2
MM;X&<5$F%B"(XQ4V0:K2'8:=$^XUFP1*4IA&*MJF5J*1<5F:%>E%&*>%ID#T
MI[#BFCBG]::&F5)$YJ2 ;2*F,>:C;Y*NPC02956H)[M1WK-FO-BGFL.]U7;G
MYJ<4.YK7NH* >:YJ^U11GFLG4-:QGYJY6_UHY/S5TQ$SH;K5AS\U85[JN0?F
MKG+G6"<_-6;+J1<]:3EJ0U<T+Z^9B?FK!N)G8]:G:0R5$8B:TB[D;&;(&)J+
M8:TVM_:H6AQ6R'<6R7YQ77Z5C*URMLN&KIM-;!6LYA8]+\/D96O2-.(\D5Y=
MH$G*UZ3ICYB%<LD!J/TK(O\ .#6P!N%9>I+A34I@<5JS?*U>:^(#G=7HFL-@
M-7G6M\[JUB-(X"['[TTR'[PJS>)^\-54.&K:);1V>@8W+7J.B_<6O*?#[_,M
M>IZ(?D6B3$M#L;,\"M>+D"L:SZ"MB'H*SD] +(48J&4 58!XJM.:Y9;C17+<
MT]22*KYRU6X5R*J(%>9216%J4?[MJZ:6/BL/4D_=M]*U3$>4>)$QNKS>^'[U
MOK7J'B9/O5YG?+^];ZUHC-F;CYJV-.4Y6LL+\U;NEQY*TV!UVB@[EKT[0<[5
MKS[1H>5XKT715VA:S:'8Z^$_(*<W2HHC\HIS'BLVAV*L]4^]7)>:K[>:QD6A
MR"IUIJ+2GBH+3),C%-:HM_-/4YH&)2T[;3330T1O35^]3SS2HO-,HMP"K\0J
MG"*O1T7$V6DZ4^F)TI]22%)2T4F E+110@"BBBF 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !2'I2T'I0!EWR;@:X_6+;*-Q7<7"9!KG-5@S$W
M%=%,SDCQ'Q1#MW<5YK=#$[?6O6O%L.-_%>57JXG;ZUT1(O8;#4]5X^*L+S73
M%F4F(:::E(XJ%^*U1##-.J('FIEK6+,WH)BC%/Q28JKDW%%+FF$TF:D+$E%,
MS2BDQ6'44E-)I(!33*=1BG<8HI33:*8"8IPHQ12N IZ4P]:,TE,:'K3^U1 T
MX-2&*U-IW6D-43<6D-)FBE< IPI*2BX"FDH!IV*:8;""E-)29I,!#0*=BDJ6
MP%I:9FG"H86%HI#3<TD%@-)2TN*H8HI:9FE!H$T/HI*:333%84TTT9S2XIW'
ML IW:FT9J@$-**6BE<!>U--&:*8""GBFXHS23#<4TW%+2XHN "@TE%,!#UI1
M1BCI4@.I:8#3J0F%(:":;FD"0&@4M+BJ3&+VI#29HJK@)WIXI,4E),!33>]+
M2XH; !2FFT4P$-**7%)2N [M3#2YHH; 04\=*;1FA,-Q]%-!I34L04TTA- I
M)CL%.%&*2K3 <:;1FBK0TA12FFT9J6%A#3EIM+2*L2YXIAI,T9H!"4ZFT5+-
M$Q&%-Z5)3''%92'N.BG*MUKL- OB&7FN#+8:MW2;HHR\UDYE*)[CHFHY5>:[
M?3KH.!S7C&B:E@J-U>DZ)>[PO-8U-4:1T.\C?*U(#5&VEW(*N*<UQ-6-"2D/
M2EHJ2D1D4"G$4 4[C%%#+D4HI:0&1J, =#Q7#ZSIVX,=M>C3Q[Q6%J-B&1N*
MVISL9R1X/XAL=F[BO/+M-LYKVGQ58[0_%>1ZI 5G;BNE.Y&Q!;-C%6F8$5G*
MQ6IEES6T60]0E&:HR\5HD96J%P*)2%%:C;?EZZ;3(<LM<Y9C,E=IH\&2O%9)
MW-&COO#$&&3BO6](3$"UYMX<AP4XKT_3!B$5S52HFCBE%%%8%BTM)2TB@HHI
M#0!&]59#5B0U4E-0]2T5I35.2K$K558YH1+(6'-/0<T$4H&*L1.E2@\5 IJ9
M>E7 AHK7)X-<WJO^K:NCNNAKF]3^XU="9FSRWQ,I.ZO-;U#YK?6O4_$,>[=7
MG=_#^\;BKN5$Q4&&KI]&/S+7.E</6]I+89:931Z7H9^[7H^C#*K7F&A2<K7J
M&A<JM9R=B5$WY%^2LV3.^MF1/W=94R?-4IW+2+-I5Z3'EUGVYQ5J23Y*B2&9
M=V?F-,MV^84MSR34"-M-2*QMQR#;4<C U32?BI-^:AHH=4@%,6I12$T%*#BB
MF,<52%8FW@"LZ]N0@/-.EGV@\USFK7VT-S6T4!#J&IA<\UR>HZKU^:JFJZJ0
M6^:N2OM4))^:J6A*+U_J9.?FKG+N\9B>:KSWQ<GFJF\R-5I@R7YY#U-3164C
M'O6AIMEYI'%=99:'N4';2<+L$SE8-.?'0U,]D4'(KN8]$ 'W:H:CIWEJ>*U@
MK$-'$RH%JE+C-:6H#8Q%9#OS6Y-B6#[U=!I_WEKGK<_-71Z</F6LIL:9WV@9
MRM>E:4#Y8KSGP^O*UZ7I2_NA7/)CW-B,?+6;J@^0UK(/EK,U0?(:QOJ.QYSK
M?\5>>:Q_%7H^MK]ZO-];XW5M!C.+O#\YK/S\]6[UOWAJ@#\]="'<[#P\?G6O
M5]#^XM>3^'OOK7K.@CY%I,+'8V2\"MF)<"LVP3(%;2)A:PDPL)T%59ZM-Q56
M7FLF.Q4 ^>K\ XJH%^:KD7 I(+"S$ 5A:FP\MOI6Q<O@&N<U27]VU:Q$T><>
M)F'S5YI?']ZU>@^)9,[J\WO7_>M]:V1FT0*?FKH=)QE:YE6^:NDTAN5IB/0M
M& ^6N^TG[JUY_HQ^[7?Z3T6H;+1TL9^44XM4:?=I"U9-E"-S3,<T_K2XK&0
M*:YXI2<4PG-2-$7>IXZCVT]>*19,3Q43&E+<5"S4 /S4D?6JX-6(NM.Y2+T(
MZ5>C%58!TJ\B\4A,D6G4@I:!!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $,BY%8^IQ9A;CM6VPS6??QYA;Z5I&5B6
MCQ;Q=!]_BO(]0AQ.WUKW'Q7;YW\5Y'JEMB5N.]=4'<QD<Z!BIHS39EVFDC/-
M=,$9-%KM5>458'2HW%;I$E91S5A!3 M3**M$3%Q2$<5(!0PXJC,K-3:D<4P4
MBD%.%&*0TFQ#B:;1FE I)AL IU%+0(812"GXI"*H=PH-)FEZTK ,HIY%,-4-
M,*44 4['% -@*4TVC- A#2BEQ24F M--&:<!0D&PT4_-)BDS3#<#2"EI<4FP
M%%--.HJ6(CI12D4AJ6BMQ2:;0*<!0D&P**=12U1)$12BG8I.E(=Q<TTT9I:;
M0#0*D%)BEI(38AIM/I"*H:8#I0>E-S10 4X48I: ; TPT^DQ2$F(*6DZ4F:8
MP- I12XH"XM--/I*0A@IU&*;3'N*:3%.'-+BI92&BE-(>**:):$I12XI.E,!
M:0]: :<!1L-(:*6@C%)F@&A#0*44N*!!0:;FG#F@$AM.%+BFF@;0IIM+2XH$
M(*4TAHH86$Q0*>!2$8J2@I#1FG@52$D1XIU*13:HI!28IX%+MI,!E%!I*!W"
MEHQ10T 4E+14M#%%-?D4M'6LY(M,INAS5NT8H12^5FD(V5S2CJ;19U&DWNUU
MYKTSP_J(PO->*6=WLE'-=WH>I;=OS5#*L>YV%\&5>:W;>3<*\VT;4MX7YJ[S
M3)MZCFN:HBD:XI:0'BEK L**** "BBB@!",U5NH@8SQVJW44HRAIH31YCXIL
MMZO@5X[K>F,)6.*^A=9LO-#<5YMKNCC#';7;2>AA+<\9N8#&34$;<UT&MVGE
M,W%<T#AZUY@MH:*GY:IW%3HWRU!+S4R>@EH2:>F91]:]!T*#.WBN'TM,RCZU
MZ7X?@R%XK-.Q39W>@PXV\5Z%IXQ$*XW1H<;>*[:R&(Q6%1W+@6Z***R*%I:2
MEI%(*0TM(:3 @EJE*:N2]*HRU)293EJN>M3R5 :!"BEQ2"GJ,T[B!14R]*:J
MT_M6D!2*MR.#7.ZDOR-72SC(K"U&/]VU;)F31YIKR_>KS_4%^=J]%\0KC=7G
M=_\ ZQJU2!&'(/FK3TY]K"L^0<U8M7VD515ST+0[@;UYKU?P[*"JUXCHMSB5
M>:]<\,W&53FLY:CN>A$YC_"LZ9.:MQN&C%,=,U*5AW*Z<4]F^6D88IF:&%RO
M*N:K%#6CY>:8T/M6=AE)0<U8C%+Y7-2HF*307)$6I@M)&M6%7BHL"9788JK.
M^!5R48K)O9-JFKBAE"\NMH/-<9K=]PW-:VIW>W=S7":U>Y#<UJF2SG]6O27/
M-<W<3%CUJ?4+G=(>:I+\YH3N)(;'&TC=ZU;/36=AQ4NFV?F,.*[G2-&#[3MK
M:,12(=#TDY7*UW]AI8$0^6G:5HP3;\M=;;V 6,<4.5B3GVL %^[7,:[;!4;B
MO19[;"GBN,\1181^*TB[BN>.ZRNV1JP'/-=+KJXD;ZUS,G!K03)[4_/73Z;U
M6N6M3\]=5I?5:SFA6/0_#_5:],TO_5"O,]!ZK7I&EM^[%<\D6C>7[M9>J?<-
M:*'Y:S=3^X:Q:U'<X#6^C5YIKH^]7I>M=&KS?7!]ZMJ: X"]'[PU27[U:-ZO
M[PU0 ^>N@$==X=^^M>N:"/D6O)?#@^=:]=T$?NUH'<[?3^@K8!^6L6R. *U-
M_P M<\UJ-,21JKL<TLC<TP'-0T.XJKS5E%XJ*->:MHORU%K!<S;TX4UR>K38
M1N:ZK5#M5JX+69\!N:UAJ2V<+XADW;J\^O/]8U=QK4FXM7%7B_.:VL1<H+]Z
MNET?EEKFL?/73Z(,LM*X['H.C+]VN_TD<+7#Z*G"UW>F+@+42$CH%^[32*<G
MW:4K6++&J*<:4"D-9L")J:*<W6D%(8H%.Q2@4_%3<I,@;I4#=:M2"JK]:8QR
M#-6X5YJO$,FK\*=*129=MUJZHXJO"N*M#I3$ I:**!!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1124K@+124M%P"BBBF 55O%S$WTJU
M4%P,QFF@/-?$MMOW<5Y3K-EAV.*]NUJVWAN*\VUZQQN.*Z:9C+<\GODV,:IQ
MMS6OK46QVK#0_-77"1#6AHJ>*1C4:-Q2DUT19BQ14BU$#4JUHB&2"ACQ3<TA
M-49LC>F"I#3#4W'<7---&:6DT T4\4A%)FD&X^EI@-.H0A::3033<U:&D)3@
M:92TQDF>*810#3@*!;""G9XI#3<T!N*:04X4$4!<4'BD--S2T (.M.%&*2DF
M&XIIN*6EQ0V @IV:8: :BX6)*2@4AIH0&FD49I>M#0]AHIXI,4F:$@W'TM-%
M+0(*::":*8Q*44N*2@!U+3 :=2$T%(:#3<TQI :!2@4&@!:6F9IPI":'4E%,
M)H!(4TE**7%,8"EIE*#0%A])12$TA 33#2YIM4BDAZT_/%1 TX&DT,4TWO3J
M*!-A330324(5A1UIX-14[-*10]J92YI<4)B;$%*3330#1<04X48HIC3'9IAH
MS2T#;&BG44W-!.X&@=:2@4RD2@TAI@-.S4V ;4BTVC.*=Q7',:C[T$TE,9(I
MIQ-1 TN: %--IU)3*%HIM+0V-!1125(!3EZTVG+4M B=1Q5>XZ5.IXJO<=*P
MDC2+*D;E9:Z72KS85YKE3P]7[2X*$<U@T;7T/7] U#E>:]3T2[W(O/:O O#]
M_P#.O->N>'[[*+S64XW!2/1HYMP%6 <BL6TN-P'-:T;9%<LE8T3):*2EJ2@H
MHHH *:_(IU---";,N\AW@\5QVNV(,3'%=])'NKG]9M<P-Q6\)V,VKGS_ .)[
M3#OQ7!2Q%9#7KGBFS^9^*\TO;?8YXK5.X[&<&P*:6R:9*=IIBMDT[D-&YHZY
ME'UKU7P[%PE>7Z&N95^M>N^&XOE3BI:$CNM+CP%KJ[7A!7/:?'@"NAM_NUA-
M&B+-% I:S*"EHHI%"&FDTIJ%VI,:&2M5&4U8D:J<IJ&.Q6D-0$\T^4U#GFA"
M9**D6HUI^:JPB8&G9J$-4@-:1%(;(,UE:A'^Z:MC&:IWT>8F^E:H@\I\1QXW
M5YKJ Q(U>J^)HOO5Y?J:8D:MHL1@RG!I8FYJ.X.#386YIW"QTFDR8E7FO5/#
M=YM5>:\BT]]KBNZT:^V;>:+"/9K.]#(O-:2-O%<)I6H;MHW5V-C,'4<U+129
M8=*C$9S5O (I5C&:A@0I%Q2M%[5;5!2E!47*3,XQ<TFW%7F055DP*:U!B*V*
ME$@Q5(R@4SS_ 'H<24RU*^16'J380FM+S-U9.K-B$T)#N<)K=UM+<UY_JUWN
MW<UT_B.XVL_->>W]SN8\U7*3?4S;E]TM6K.$L15#.Z6N@TN#<1Q5PCJ5<Z#0
M[+++Q7J.A:>-J_+7'Z#:#*\5ZEH=J B\5I*7*+<TK.T" <5J!0$I$BV@4CM@
M5BWS,EZ%6ZQM-<-XC^Z]=G<O\IKBO$+?(U=$$0SR+7A^\;ZURLW4UUNN_P"L
M;ZUR5SU-;#3%M3\]=;I1Y6N/M3^\KKM)ZK6<RK'HV@CE:](TQ?W8KSOP\,E:
M],TQ/W0KFDQF@G K.U+[AK3/ K*U$_*:SW9+.$UD<-7G&N?Q5Z5K X:O--?X
MW5O $SA;T_O#5)1EZL7C?O3440RPK9(9UOAT?.M>MZ%]Q:\H\/C#+7JNAGY%
MIV$=K9#(%:>WY:S]/Y K9"?+7--ZCN9[H<T*AJTZ#/2E5!4!<C1<5-OVK0P
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M9<UWWBC[[UY]<??-4A$</,@KK-'7[M<K /W@KJ]).-M:Q15ST30L K7INC.
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M1<I(DB6KT25!"E7XTXJD421BIA3%%/I$,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EI*E@%%%%*XPHHHH 6BDI:I,04AHI*H39#(N0
M:YK78-T3<=JZDC(K&U:+=&:T@S-H\.\2V66?BO/+^TVL>*]HU^QW%^*\VUBS
MV;N*[H/0ROJ<+*NUJ=&:DO$VR&H$-;Q"6J+BFI5JNAJPO2M$<\D+29H:F9YJ
MDR+$E%(*#TJR0)IAH)I14E"8IU!%-- ;BFFT4520QXI2:9156%8*<*;13 ?F
MF&C-%) **?FHZ7-4#0II*44IJ6Q!FFFD)I:EL=A,4X48IIJ0W'TM,!IU(3"F
MDT$TVD-("*<*4"D--!<=FFFDS25H@L**?GBF44V%A33:4TE*PQX-!IM%.PK"
M4\&F4N:5ACB:91FBD"0HI^:CI0:!-$E%(*0U/40N:::3-**8]A *<#13<T)A
MN.--Q2BG8I@(*":0TV@+!3U-,I0:11(33#1FEIH: 4_/%1T9H"PK4@HHI#L2
M \4UJ;FC- K!WIX-,HS2'8<33*7-% )#A2DTRC-%A"&G+244#L/S3#1FB@+"
MBGYXJ.C-,30K4@HHIV"P\&D8TW-(32$)WJ134=+F@"0FF$4N:7%,38@H)H--
MS0(#2J:;2T[%$N:::;FG4;";$%/SQ3:0FC<$P8TPTI--J6,*D2H\5*E2T-$A
M'RU4F%7"?EJK,*RDC1$"-M-:MA=%9%Y[UC-P:DMYML@YKFJ&RU/8O"]_@KS7
MK.DWX,2\UX!X>OMI7FO4M%U+**-U<SC<>QZ;#/O[U:!XKG].N=X'-;B-D5BT
M4I$U%-%+4EW%HI** N+4<@R*?2'F@+F5=P!E/%>?>*+/*/Q7J$L>5-<9XCM=
MR/Q5)DV/GGQ!9?OFX[USOD;6Z5Z/K]A^\;CO7'7-ML8\5:%<O>'A^^7ZU[=X
M5CRB5XMX?7_2!]:]R\)I^[CJF["L=Q;)A!5U.E10IA!4XK)NY:T%I:2EJ"PH
MHHH 0U&QI[5"YJ9%(J3GK69+UK1F-9TO6A%$.:4&HV-"FD0R<"GBD04XTTP%
M)XJ%J<349JB621M@U9\SY<51W8I1)S6D2"&\B\P'BN+UVQRC<=J[X)O%8NM6
M>8CQVK:+(9X)K]EAVXKCYH=K&O5/$5A\S\5P5]:E2>*UZ F80.UJNP2XQ5.5
M2KTJ/BG$HZ.SN]I'-=#9ZGMQ\U<)'<%>]6H]0*]ZTM<1Z?::UC'S5JQ:X,?>
M_6O)X]7*_P 57(M:/]ZCE ]2_MD'^*H)=8_VJX&/6"1]ZF3:L<?>J6@.PN-9
MX/S5DW.K9/WJY.;5C_>JD^IDG[U2XB2.S@U'+?>K=L;S<1S7G%G?$L.:ZO2[
MDL5YI6&W8]*TN7=BM#45S:_A6+HC;MM=%>1YM/PI6,VSQ_Q/%\SUY_<1X<UZ
MAXF@RS\5YY>0X8\55A)F7'P]=!IT^W'-8#?*U6[>?:1S5P*N>C:5? %>:[C3
M-2  ^:O(-/OMI'-=98:G@#YJVL0Y'JUOJP 'S5+-K(\O[U><KK&!]ZFS:V=O
MWZYY4[LI3.BU/50=WS5P^L7V[=S4=YJQ;/S5S=_?%L\UK#1"O=F9J4VYSS6,
M_)JQ=2[FJ!.35M%HM6*X<5V>E2A=M<A;#!K>LY]F.:AB;/1=-OPFWFNJLM7&
MT#=7E$.H[/XJU;36#N W5E)"/6(M2#C[U17=QN4\UR>GZB7 ^:M8SEUZU 7,
MW4_F5J\]UU?O5Z'>#<AK@]>3AJN"U \[O5_>&J8&#6C>K^\:J)'-=444F:VF
MS;&7FNSTW4@@'S5Y[#+L-:5OJ!3O0T.YZU8ZP !\U;":X OW_P!:\CM]7*X^
M:KPUPX^_^M8R0KGJ#:Z/[_ZU3GUP'^.O.FUP_P!^J\FM$_Q5E)$7.VN]9R#\
MU<[?:INS\U<_-JQ(^]69/J!8_>J4K%+4O7MYOSS6#<$NU/:X+GK30N\U16Q7
M6$DUK:=:DN.*;!;;CTKH=+LLN.*EQ'S&YHUE]WBO1M#MMNWBN=T:QX7BNXTV
MWV8XJ6A[G2V8"Q"GRM44)VI22-6;5A)$3M4!;FG.U0$\UF]2BU&:G[55C-6,
M\5#15P)J)J5FIF:@0G>GJ:;29Q0T4D65YJ9$S5>$Y-:,*9%"*3'1)5U!Q3$3
M%2@<507%I:**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !24M%)H!**6BE8!****0PI:**I(0E)3J2F)H3M5"^CW(:T*AF3<*I;B9P6K
MV.X-Q7F7B.RV!^*]QOK,,C<5YAXLL]JOQ75"9@UJ>'ZDFV8U31:UM8A(N#Q6
M=&E=4)"D2(M3J.*:HJ2NA&#9&]1]ZE:HC02/4TI-,%.%:+8EH3%**6D-(!:3
M% J0#BG8:1%BDJ1A4=4F,6C%.%*13N3<9113EI@)BDJ0BF'K0"8E+B@4_% -
MB"@TAI*30A"*6G8I#4V'<*0BC-.Q18-AHI<T&FTF@W%/-)BGBE(J"AM!I#0*
MI(EH3%)4F*::M F)3L4+4F*H9$124]A3* #%%/ I"*5Q7&T8HIP%# ;BDIY%
M--*PTQ,4N*4"G8I-"N)24AI12L F*44[%--%@%S3<4"G@4)!L-'%.S2&FYI@
M*:3%.%!% 7&48I:<!3L.XW%+3B*8:0TQ>M&*44_'%(9'12M2"@=Q<4E2 <4U
MJ!7&T8H'6G@4 V,Q13R*CH&F+BC%.44I% KC**#2K0.XF**DQ49H$F%&*!4F
M.* ;&4E*U(*=PN&*0BI *1A0(CI<4=Z<!3L)L04[-(:;FD+<<:;BG"EQ0!'2
MT&E%6AABG"EQ330T3N+32*44[%"#8C(I *>10HYI-%( E.^[4R+Q44W J&7$
M9YE-(W5 7^:K4/S5BS6Q6DB]J@52KBM5XQBJ;IAJYZB&I6-K2;GRRO->@:'J
M7*C=7E4,WEGK73:)J!$JC-8M#O<]\T.ZWJO-=?"^5%>9^&;W<J<UZ#:3!E'-
M8214356EID9R*DK%FR0E)3J2@30444M TAK#Y:YO6X=ZMQ73'I61J,6\&A#9
MY%KFGY9CMK@]2LMK'BO9=6L-P;BO/M9L<,>*U1G8YS0X<7(X[U[?X37$:5Y'
MI%L5NNG>O8_"Z81*F3*1VT0^04^FQ_<%.Q695@I:**!A1110 UJ@>IVJ!Z31
M2*4U9\O6M">L^7K4[%%9A2H.:<12J*1#)DZ4XBFK3Z:)N1,*C-6&%0/5H4B,
MT!>:<O)J4+6T$9W)(N!5744\R,CVJQG%1R#>,5HD2>>ZUIGF;CMKS_5])*[O
MEKW*ZT\2*>*XG7=* #?+6B8['B5[9%7/%9SQ%:[C5=/VNW%<U=6I4GBJ0[F.
M>*;N-3R0D'I4)0UHF,!(?6I8Y2#UJ$*:4 BJN!I1W!'>B2<D=:HAB*=N)K-L
M D<FJY8YJP5)J)HSFIE(:+VGDEA7;:.I)6N-TV([QQ7>Z+"<KQ4*1,CO] C^
M[76SPYM>G:N?T"+&VNP>+-M^%2Y:F=CROQ%9Y+\5YSJ5IM+<5[+KEINW<5YS
MK-GC=Q6L7="L>>7*;6J!7P:TM0@(<\5E,I!JD[#M<T;6XVD<UO6M_M YKD4<
MJ:MQW1 ZUHI X'6G4N/O5$^HD_Q5S9NV]:%N&8]:4I H&W)=%N]9]PY;-)$6
M84]XF(Z4E(7+8RI5YIB\5=D@/I55T*UK?0I$T4F*O17..]8P<@U(LIJ),+&W
M]LQWJY97I,HYKF3,:O:<[&9:YI3*2/4]$D+A:ZV-"4KC_#:EE6N\BB_=CZ4)
MW,Y&;=1_NS]*X+Q ,!J]&O$Q&U>=^). U;1!,\ZO3^]:JFW-3WA_?-3(QFNA
M2*L1[30"0:L;,TQHCZ4.0@28CO4GVD^M5F4BH^:PDRK%TW!]:89CZU6R:<,F
MH;(:'M(2.M5W8DU-L)IIB)[5*''09&"35^VCW,*AB@.>E:MC:DN.*H;9J:?8
M^9CBNPTK2CD';5?0]/W;<BO0-,TP!5^6I;&D+I6G[0O%=+;V^T#BGV=D% XJ
M_P"4%%9.1:(QPM0R-4S\"JLAYJ&QI#3S0(\T)R:N)'Q6=QM%=5Q3R>*D=<5
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M_P -=3;Z7G'RUIP:3G'RTE(?*<E;:*21\M;MAH1W#Y/TKJ[+1@2/EKH[/15
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M,4N:#3<T@W'&DQ2BEQ0 E!I#0*JP!BE'%+BFFI 4FDQ2 T\4!L(*7-(:2J2
M"*,4X4AJ6 9H/--S3A0 W%%/(IAJD%PQ2XH%.Q287$'%!.:0T@-(+"XI,4\4
MAIH+C*7%%/ IL&QM+F@TW-2&XM)BG"E(H07(Z7%%**IC#%*#2XIAJ1;CB<TF
M* :=B@-AF**4T@JN@PQ1BG@4AJ17&4M)3A3*0F*=1106%-IU%,0E+3:>M KB
M;:0BI<<5&PIDC:7% IU)B8E*#2&FYJ6!*#2YI@-(34M@AV:3&:9GFIT&:S9:
M(MM*>!4[+Q5=ZS:*W(9.:8@PU2&D YJ66G8OVDA5A7?^&KG#)S7G,+885V&@
MW&UEYK-QN:)GNFAWG[I>:ZF"?<!S7F>B7_RKS7<:=<[P.:YJE.QM%G0*<BG5
M'$<K4E<K+"BBB@!*3%.I*!6&.N5K+NH0<\5KMTJI+'FF,QX[?#]*UK9, 5$L
M/S5<B7%%P)ATI:!12 **2BIN M%%%4!%+TK-G'6M.3I5"84FP,UQ4)ZU9E%5
MCUJ=Q-B@4XBD2I".*I(5R$THH/6E6J$+BFFI>U1MUH'<C(S2;*D S4@3BJ1)
M %Q4BFE9<4SH:=P)U:G=:A#4\-1<JPV2,,*S;BS#YXK7'-.\D-2YB6CC;O3,
MY^6L.ZT?)/RUZ1+9JW:J,NG*>PHYA6/,9M$)_AJH=".?N5Z>^E*>U1'25]!5
M7"QYL-"/]RIDT$G^"O0QI"^@JQ%I"_W13N,\_A\/G/W*U;;1"N/EKNH](0#H
M*F&FHO85/,!R]MI>W'RUK6]GMQQ6LMFH[5((0*$Q-%:*':.E6-O%2!0*#BG<
M:*DD>:SKFWSGBMAAFH)(@:.8=CEKJQW9XK%NM*W9^6NY>V![5";!6[4*1-CS
M>;0BQ^Y51O#I)^Y^E>H_V6A["G#1D]!0V,\VMM!*G[GZ5O6.E;6'RUUG]DHO
M85-%8JIZ4KCL0:?9!5'%7+FU!3I5^WA"BI)HP13N*QQ-_8;L\5RVH:3NS\M>
ME7%L&SQ67/IP;M5J0CRYM")?[E68- .?N?I7H"Z0I;[M7X='7'W:OF%8XJRT
M4H1\M=+8V&S'%;:Z8J=JGCM@IZ4T2Q;.#:.E+?IB,U>A0 55U#[AJ+Z@<)K
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MTBU*.E 6(2*04]J:.M "A:7&*>.E(W2@!N:,9IN>:D7I0*PPK334S5$>M P
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M* (VI%7)J0C-.C3F@!\<6:OP1XQ3(8ZO1IB@":)<"I<4U13Z "BBB@ HHHH
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M#4$TP&EH0PHI:::H8$TE%%2(<#3\U%2B@0^DI12&J)#-%-[TX4K@%&:4TVJ
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M,6BBB@04R094T^D(S0!SVHV7F \5Q6LZ/E6.VO4)(0PZ5BZI8JT9XJXLEH\
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M%+2TVF,<*7;2+4G:D(B(IM/:F=Z!"XHIPI#5%!3L4P5(M2(:13#4S5$>M @
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M4I%1,IH D0YJW''FJL"'-:L"<4 .BBQ5Q4XI(TJ<#B@!@6G 4[%&*  4M%%
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M&:**;!!FBBDH0,>#1NIE%(!31TI*6F 9HHQ1VH0-B@T[=4=%)@.)S24E+3L
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M5IU, ZU(L6ZFHIS5Z&/B@!D4.*O1+BE2/ J55H D6I!3%%/% "T444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ391Y=)@14M2>71LI(".ES3]E'ET,".BI-E&RF@(J<!3_+YJ18JEC(]M&VK
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M"5(R$14X0U8"T\+181 L6*D"5+BC%4D!'LI=M244P& 4[%+10 4444 %%%%
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MJ:DQ0!%Y=+LJ7%% $/ET>74V*,4 1;*3RZFHQ0!#Y=+LJ3%+0!#LH\NIJ3%
M$6REV5+10!#Y= 2I<4N* (ME)Y=348H A$=+LJ7%% $)2CRZFQ28H C"4[;3
MZ* $Q12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "444M2@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EHHH **** $I*6DIDL6
MEI*6D-!24M% Q*6BB@ HHHH 2BEI*D!:***H HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH$Q*6DI
M:8D+1112*"BBDH 6BBB@!#3&-/-,84 ,!YJ04P#FI * %[44M)4L %+244 %
M%%+0@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "DI:2I8"T444T 4444P"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $I:** "BBB@!*2EI*9+%I:2EI#04A%+10,;BEQ2T4 %%%% "4445("T444P
M"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %)BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $4
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[]CGYL>V!Z>O6D!.,DY'H!_G_#OFE(S[ \D_3H*R-8UK3/#^G:
MEK6MZE8Z/HFBV-WJ>L:IJ5W:V.FZ7IEC;O=7NH:E>W<L5M9V5G:QR75S<W$D
M44$,4DTLB1(Q)&,IRY8J[;TBK\TI72M'KJW9)=1-I1D^:,5%<TI2V2^?Y7V^
M1IEV'L.?F.#C ZE1T7URR>Q/6D$O')Y^4Y!0Y#< A5+':2.IQC/4@&OXF/\
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M3>/Q_P"$HI__  U1^U*#S^T]^T1GN/\ A>'Q,_D?$Q/IU-)?1[S;_HH<(_\
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MC<,L1:.6$1RLTA_37PUX@L?$V@Z7KVFL#9ZC:Q7$8R/W7&V>!@/NO;2AX77
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M/P)?^!?#$_@ZQN;20R6US:>&9M+;1K:YC8DK<P64<S [7=EPM?;?_#,/B?\
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FC''^?RHVCT'K_G\J**32>C2:\UYW_-( Q@8'2EHHI@%%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
